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Abstract
This research aims to compare and apply Bayesian models for patient survival
using gene expression as explanatory variables. Three models were examined; the
Weibull model, the Weibull mixture model and the Weibull cure model. Bayesian
model averaging (BMA) was developed to produce better descriptions of genetic
contributors to survival and of subgroups of patients with different survival charac-
teristics. This can in turn provide insight into improved treatment regimes for these
patients.
In the development of the methodology, some important issues such as the effect
of censored data were addressed. This research indicates that censoring has an
effect on the performance of the Weibull mixture models in that as the proportion of
censoring increases, poorer parameter estimates were obtained in terms of both bias
and precision. Censoring also had a different effect on estimating the parameters of
the mixture model, depending on the “closeness” of the components.
The application of BMA to combine the three competing models produced more
robust predictions of survival time. BMA also allowed the identification and analy-
sis of more detailed relationships between gene expression in given phenotypes and
the survival times of the patients.
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Chapter 1
Introduction
1.1 Background
In analysing the factors influencing the survival of patients with a given disease, var-
ious issues can be taken into consideration as explanatory variables. Amongst these
is the biological system, in particular the gene expression of the patients. In relation
to this, this research used gene expression data to aid in modelling the variability
in the patients’ survival times. These data typically come from microarrays. The
significance of microarrays in genomic studies has been widely acknowledged. This
is due to the fact that microarrays can provide information about a large number
of genes that may be potentially important for biological functions (Newton and
Kendziorski, 2003, Segal, 2006). This information in turn allows the examination
of the variation, roles and interactions of the genes in relation to the survival time
of patients.
In this thesis, we focus on Bayesian statistical approaches to modelling survival.
Although there is a large literature on Bayesian modelling and analysis, the litera-
ture on Bayesian survival is still growing and there is only limited literature to date
on Bayesian survival modelling using gene expression data and that consider model
1
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choice issues and sensitivity analysis to censored data. For example, Kaderali et al.
(2006) proposed a Bayesian Cox proportional hazards model for this purpose. In
contrast, Lee and Mallick (2004) adopted a Bayesian Weibull model, following
the notion that the Weibull distribution is a popular parametric distribution for
describing survival times (Dodson, 1994).
Given the nature of microarray data to describe biological systems and outcomes
of patients, and hence the potential of these covariates to produce more precise
inferences about survival, the use of a single parametric distribution to describe
survival time may not be adequate. Microarray data may enable the description
of several homogeneous subgroups of patients with respect to survival time. This
research therefore used Bayesian Weibull mixture models for better estimation and
prediction of this outcome. Mixture models are commonly used in describing data
consisting of several groups, where each group has different properties and features
of the one family but use the same distribution. These models provide a convenient
and flexible mechanism to identify and estimate distributions, which are not well
modelled by any standard parametric approaches (Stephens, 1997).
In relation to survival analysis, one fundamental issue in the use of Weibull
mixture models is the effect of censored data. Censoring is an innate feature of sur-
vival and reliability data, and occurs when part of the lifetime distribution, usually
at the end of the study, is unobserved. This may be due to a variety of reasons;
for example, some patients may still be alive at the end of the study period so the
event of interest, namely death, has not happened. There is developing literature
on the application of Weibull mixture models in the field of survival and reliability
analysis. Examples of these are Ibrahim et al. (2001b), Farcomeni and Nardi (2010),
Qian (1994) and Tsionas (2002). However, only limited attention has been paid to
the effect of censoring on the mixture.
1.1. BACKGROUND 3
Models for survival analysis typically assume that everybody in the study pop-
ulation is susceptible to the event of interest and will eventually experience this
event if the follow-up is sufficiently long. In recent years, there has been increasing
interest in modelling survivor data with long term survivors. Most approaches to the
analysis of time to event data implicitly assume all individuals will experience the
event of interest. However, there are situations when a proportion of individuals are
not expected to experience the event of interest; that is, those individuals are often
referred to as immune, cured or nonsusceptible (Ibrahim et al., 2001b). To address
this issue, cure rate models are considered, which are survival models incorporating
a cure fraction. These models extend the understanding of time to event data by
allowing the formulation of more accurate and informative conclusions.
The problem of model selection is abundant throughout the literature. This in-
cludes both covariate selection and choice of the model itself. Some of the methods
are based on a series of significance tests (Mosler and Haferkamp, 2013) while
others fit more comprehensive models; some include prior information; some use
analytic or approximate methods of estimation while others use Markov Chain
Monte Carlo (MCMC) methods; different approaches use different optimisation
or model comparison criteria such us the Bayes factor (Raftery, 1996). Regardless
of the method, the most common approach is to choose a single model based on
the adapted optimisation or model choice criterion. However, if a single model
is selected then inferences are conditionally based on the selected model, which
often leads to excessively narrow or misleading inferences (Hjort and Claeskens,
2003, Raftery et al., 1997). This difficulty can be overcome by combining the
information provided by all suitable models into the analysis. The most common
way of achieving this is to use a form of model averaging. From a Bayesian point
of view, this averaging is applied such that posterior distribution of the quantity of
interest is obtained over the set of suitable models, then weighted by the respective
posterior model probabilities (Raftery, 1996). A variety of methodologies exist to
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compare several competing models for a given dataset and to select the one “best”
fits the data. Bayesian model averaging (BMA) is one way of combining models in
order to account for the uncertainty. By averaging over many different competing
models, BMA incorporates model uncertainty in inference and prediction. Hence,
in this thesis, we also consider the problem of predicting survival, based on three
alternatives models; a single Weibull, a mixture of Weibulls and a cure model. In-
stead of choosing a “best” model, we adopt a model averaging approach to account
for model uncertainty in the prediction of survival.
1.2 Research Aims and Objectives
The primary aim of this research is to develop and apply a Bayesian modelling
approaches for prediction of patient survival using gene expression data. This
research aimed to develop a new methodology that allows a better description of
genetic contributors to survival and of subgroups of patients with different survival
characteristics. This can in turn provide insight into improved treatment regimes for
these patients.
Specifically, this thesis focuses on two distinct areas, covering both statistical
methodology for Bayesian survival models and the application to gene expression
data. The research has the following objectives:
1. To describe and implement a Bayesian Weibull model to predict patient sur-
vival;
2. To investigate the impact of censoring on fitting a finite mixture of Weibull
distributions either with or without covariates;
3. To describe and evaluate a model averaging approach to account for model
uncertainty.
1.3. STRUCTURE OF THE THESIS 5
1.3 Structure of The Thesis
This thesis is written in fulfillment of the requirement for thesis by publication.
Chapters are presented here in the form which they were submitted, or accepted.
These articles are presented in Chapters 4 to 6. Each chapter has thus its own
relevant literature review and there is necessarily some overlap and repetition across
chapters, and with the content of the comprehensive literature review presented in
Chapters 2 and 3. Moreover, the same microarray data has been used throughout
Chapters 4 to 6 of this thesis which is repeatedly described in these chapters for the
purpose of publication. Because we referred to the same papers in several chapters,
the bibliography for all chapters appears in a comprehensive bibliography at the end
of the thesis.
1.4 Thesis Outline
Overall, this thesis consists of seven chapters and is outlined as follows:
Chapter 1 describes the background of the research topic and points out the
research aims and objectives, and the structure of the thesis.
Chapter 2 is a literature review that related to the applied focus of this thesis,
that is, the use of gene expression in survival analysis. It covers a discussion on the
basic concepts of gene expression, microarray analysis and lymphoma disease.
Chapter 3 is a literature review that provides an overview of the body of knowl-
edge associated with the research objectives and goals. The review includes a dis-
cussion on survival analysis, Bayesian modelling and computation, Bayesian vari-
able selection, sensitivity analysis, goodness of fit measures and Bayesian model
averaging.
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Chapter 4 addresses the first issue of this study, namely describing and im-
plementing Bayesian methodology to fit a Weibull distribution to predict patient
survival.
Chapter 5 addresses the second objective of this study, namely the impact of
censored data on Bayesian analysis when fitting a mixture of Weibull models.
Chapter 6 is intended to meet the third objective of this research, which is to
develop a model averaging approach to incorporate the model uncertainty when
predicting survival.
Chapter 7 presents the overall discussion of the research and describes how the
objectives of the thesis have been met. It highlights a summary of major findings
and main contributions of this study. It also presents the implications of these
findings and directions in which this research may be extended in future research.
Chapter 2
Review of the role of Gene Expression in
Predicting Patient Survival
This chapter reviews literature related to the applied focus of this thesis, that is,
the use of gene expression in survival analysis. It covers a discussion on the basic
concepts of gene expression, microarray analysis and lymphoma disease.
2.1 Gene Expression
The survival time of a patient suffering from a particular disease can be influenced
by various factors. One such factor is the microbiological system, specifically the
gene expression of the patient.
According to the United States National Institute of Health, gene expression is
“the process by which a gene’s coded information is translated into the structures
present and operating in the cell (either proteins or RNAs)” (Institute, 2013). Sim-
iliarly, Krane and Raymer (2003) define gene expression as “the process of using
information that is stored in DNA to make an RNA molecule and a corresponding
protein”. Thus proteins are the main elements of cells and the production of such
proteins is determined by genes, which are coded in deoxyribonucleic acid (DNA)
7
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(Parmigiani et al., 2003).
Gene expression can therefore determine the key functions of a biological sys-
tem. This is due to the fact that in genetics, gene expression constitutes the most
fundamental level at which the physical or biological features, as phenotypes, can
be traced. The genetic and phenotype traits can also be influenced by environmental
factors, giving rise to gene by environment interactions. Apart from environmental
aspects, the organism’s phenotype is highly associated with its related genotype.
There are two main stages of protein production from genes; transcription and
translation (see Figure 2.1). Transcription involves the production of the RNA
copy of a gene. One strand of DNA double helix becomes a template for RNA
polymerase to make a messenger RNA (mRNA). After maturation, this mRNA
is transported to the cytoplasm from the nucleus. In translation, the protein is
produced from the mRNA template via the assembly a chain of amino acids. In
this process, the ribosome binds to the mRNA at the start codon. The ribosome
continues to the elongation phase of protein synthesis. During this stage, complexes,
composed of an amino acid linked to tRNA, sequentially bind to the appropriate
codon in mRNA by forming complementary base pairs with the tRNA anticodon.
The ribosome moves from codon to codon along the mRNA. Amino acids are added
one by one, translated into polypeptidic sequences dictated by DNA and represented
by mRNA. Finally, a release factor binds to the stop codon, terminating translation
and releasing the complete polypeptide from the ribosome (Excellence, 2013).
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Figure 2.1: Gene structure and protein synthesis. Modified from http://www.
accessexcellence.org
2.2 Measuring gene expression: Microarray analysis
In bioinformatics, measuring gene expression plays a very central role. This activ-
ity reflects the effort to quantify the level at which a particular gene is expressed
within a cell, tissue or organism. One of the common methods of measuring gene
expression, is through microarray analysis. Microarrays have been used in a range
of applications such as the discovery of disease subtypes, the development of new
diagnostic tools and the identification of underlying mechanisms of disease and
medicine response (Slonim and Yanai, 2009).
In order to quantify gene expression, microarray analysis typically uses a hy-
bridisation approach. The basic idea of this approach is that a glass slide or mem-
brane is spotted or “arrayed” with DNA fragments or oligonucleotides that represent
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specific gene coding regions. Purified RNA is then fluorescently or radioactively
labeled and hybridised to the slide/membrane. In several cases, hybridisation is
carried simultaneously with reference RNA to compare data across multiple exper-
iments. After thorough washing, the raw data are obtained by laser scanning or
autoradiographic imaging (World, 2013).
In the microarray analysis, there are various issues that arise. According to
Slonim and Yanai (2009), these issues can be categorised into three aspects. The
first one comes from the experimental design. In this aspect, the main common
issues include the selection of an appropriate array technology and the measurement
of the expression levels from each sample on a different microarray or the compar-
ison of relative expression levels between a pair of samples on each microarray.
The second aspect is the preparation of microarray data for analysis, which arise
issues such as the assessment of the quality of the data, is the assurance that all
samples are comparable for further analysis and the normalisation of the raw data
i.e. removing the technical variation as much as possible while leaving the biologi-
cal variation untouched. The last issues of microarray analysis are from the domain
of data analysis, including the use of statistical analysis software packages and the
approaches taken to analyse the microarray data in relation to the desired goal of the
study. Given these issues, this research is mainly associated with the last issue as
this research utilised the microarray data that was used by Rosenwald et al. (2002)
and can be downloaded at http://llmpp.nih.gov/DLBCL/. These data, a
part from its convenient accessibility, are considered to be in accordance with the
Minimum Information About a Microarray Experiment (MIAME) standard for the
data subject to public repository (Society, 2013).
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2.3 The use of microarrays and gene expression in the analysis
of Lymphoma
Lymphoma is a type of blood cancer that happens when the white blood cells, called
lymphocytes indicate abnormal development (Pace et al., 2007, Today, 2013). This
abnormality can be shown from their uncontrollable growth or multiplication faster
than normal cell or longevity longer than they should be. Lymphoma can exist
in many parts of the body and develop a dangerous mass of cell called a tumour
(Hatton, 2008, Today, 2013). In Australia, lymphomas are the sixth most common
form of cancer (Australia, 2013a). Clearly, a greater understanding of lymphomas
has potential to save many lives.
There are two type of the white blood cells associated with Lymphoma disease,
including the B cell and T cell lymphocytes (Australia, 2013a, Pace et al., 2007,
Today, 2013). The presence of these types of cells determine the classification
of lymphoma, that is, whether it is a Hodgkin lymphoma (HL) or non-Hodgkin’s
lymphoma (NHL), named after Thomas Hodgkin, who first discovered the abnor-
malities in the lymph system in 1832 (Australia, 2013a, Pace et al., 2007, Today,
2013). The HL type is related to the abnormality of the B cells, while the NHL one
is due to either the abnormal B or T cells. DBCL which is the medical context of
this research is classified under the NHL (Australia, 2013a,b, Drouet, 2007, Hatton,
2008).
Diffuse large B-cell lymphoma (DLBCL) is a sub-type of NHL and the most
common lymphoma worldwide (Lenza et al., 2008). DLBCL is clinically heteroge-
nous in that 35 − 40% of patients respond well to current therapy, the main form
of which is chemotherapy, and have prolonged survival, whereas the remainder
succumb to the disease (Alizadeh et al., 2000, Lenza et al., 2008, Rosenwald et al.,
2002). In general, types of this disease are very diverse both morphologically and
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prognostically, and their biological properties are largely unknown, meaning that
this is a relatively difficult cancer to cure and prevent (Rosenwald et al., 2002).
Traditional morphologic subclassification often results in poor reproducibility and
has not been particularly helpful in predicting outcome (Hunt and Reichard, 2008).
There is some literature on relating DLBCL genotypes to phenotypes and to
survival. Alizadeh et al. (2000) identified two molecularly distinct forms of DL-
BCL which had gene expression patterns indicative of different stages of B-cell
differentiation, namely genes characteristic of germinal centre B-cells (“germinal
centre B-like DLBCL”) and genes normally induced during in vitro activation of
peripheral blood B cells (“activated B-like DLBCL”). They found that patients
with germinal centre B-like DLBCL had significantly (p < 0.01) better overall
survival than those with activated B-like DLBCL. The molecular classification of
tumours on the basis of gene expression can thus identify previously undetected and
clinically relevant subtypes of cancer (Alizadeh et al., 2000). Hunt and Reichard
(2008) also reviewed gene expression profiling studies and have classified DLBCL
into two main subtypes, germinal center B-cell (GCB) and activated B-cell (ABC),
with the germinal center type showing an overall better survival. They suggested
that validation of these subtypes has become possible for the practising pathologist
with the use of surrogate immunohistochemical markers (Hunt and Reichard, 2008).
However, Rosenwald et al. (2002) and Rosenwald and Staudt (2003) used hierarchi-
cal clustering to define subgroups of DLBCL and found that there were three phe-
notypes subgroups of patients of DLBCL; activated B-like DLBCL, germinal centre
(GC)-B like and type III DLBCL. These findings support the view that the various
subgroups represent different diseases that arise as a result of distinct mechanisms of
malignant transformation (Alizadeh et al., 2000, Huang et al., 2002). Based on the
hierarchical clustering, the GC B-like DLBCL had a significantly greater likelihood
of survival after chemotherapy than did the activated B-like DLBCL and Type III
(Rosenwald et al., 2002). The authors showed that these phenotype subgroups
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were differentiated from each other by distinct gene expressions of hundreds of
different genes and had different survival time patterns. Similarly, Bea et al. (2005)
also identified 3 major subgroups of DLBCL: GCB, ABC, and primary mediastinal
DLBCL (PMBCL).
Currently, prognostic models based on pretreatment characteristics, such as the
International Prognostic Index (IPI), are used to predict the outcome in DLBCL.
IPI is the outcome predictor in DLBCL based on five clinical characteristics (age,
tumour, stage, serum lactate dehydrogenase concentration, performance status, and
number of extranodal disease sites (Hatton, 2008). However, although the index is
of some value, it has not been used successfully to stratify patients for therapeutic
targets (Shipp et al., 1999) (Shipp et al., 2002).
In relation to prediction of survival, Rosenwald et al. (2002) reported a correla-
tion between outcome (overall survival after chemotherapy) and gene expression
data from individual microarray features, based on a Cox proportional hazards
analysis. Five genes were reportedly significant to overall survival; germinal-center
B-cell (GC-B) signature, lymph-node signature, proliferation signature, BMP6 and
MHC. They concluded that DNA microarray data can be used to formulate a molec-
ular predictor of survival after chemotherapy for DLBCL.
Shipp et al. (2002) reported three genes (NR4A3, PDE4B, PKC-β) that are as-
sociated with clinical outcome in the DLBCL patients by using supervised learning
methods.
Lossos et al. (2004) built a predictive model for overall survival of DBLCL
patients based on six genes; LMO2, BCL6, FN1, CCND2, SCYA3 and BCL2.
They used a univariate analysis to rank genes on the basis of their ability to predict
survival, then developed a multivariate model based on the expression of these six
genes. Specifically, Lossos et al. (2001) showed that BCL6 has strongest prognostic
significance in patients with DLBCL.
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Rosenwald and Staudt (2003) used five different genes; GC-B cell signature,
MHC class II, lymph node signature, proliferation signature and BMP6 to predict
DLBCL survival. They showed that gene expression is an effective tool for assess-
ing the prognosis of these patients.
Lexin. (2006) proposed an integrated modelling approach, which combines ge-
nomic information, in terms of gene expression profiles, and the clinically based
IPI, to predict the survival of patients with DLBCL after chemotherapy treatment.
Lexin. (2006) demonstrated that the proposed integrative modeling improved the
prediction accuracy over those methods using either clinical or genomic factors
alone.
Finally, Alizadeh et al. (2011) predicted survival in DLBCL based on the ex-
pression of 2 genes (LMO2, TNFRSF9) reflecting tumor and microenvironment.
They also used a multivariate Cox regression to test combinations of genes for their
ability to predict survival. They concluded that the measurement of a single gene
expressed by tumor cells and a single gene expressed by the immune microenviron-
ment powerfully predicts overall survival in patients with DLBCL.
The summary of result of genes whose expression predicts survival in DLBCL
from several sources are presented in Table 2.1.
Table 2.1: Summary of result of genes whose expression predicts survival in
DLBCL.
Source Subgroups Genes
Shipp et al. (2002) Undefined NR4A3, PDE4B, PKC-β
Rosenwald et al. (2002) GCB like, ABC like, Type III GC-B, MHC, lymph,
proliferation, BMP6
Rosenwald and Staudt (2003) GCB like, ABC like GC-B, MHC, lymph,
proliferation, BMP6
Lossos et al. (2004) GCB-cell, ABC-cell LMO2, BCL6, FN1,
CCND2, SCYA3, BCL2
Alizadeh et al. (2011) GCB-cell, ABC-cell, unclassified LMO2, TNFRSF9
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Following the preliminary studies of gene expression in lymphoid malignancies,
and particularly, DLBCL, an international consortium was established to use gene
expression profiling to provide a molecular diagnosis for all lymphoid malignancies.
This consortium is known as the lymphoma/ Leukemia Molecular Profiling Project
(LLMPP). It is also hoped that it will be possible to define the molecular correlates
of clinical parameters that can be used as indicators of prognosis and thus to improve
the choice of optimal therapy for each patient (Rosenwald and Staudt, 2003).
16 CHAPTER 2. REVIEW OF GENE EXPRESSION
Chapter 3
Review of Statistical Methods for predicting
patient survival
This chapter provides an overview on literature related to research objectives and
goals which are reviewed within the chapters of this thesis.
3.1 Survival Analysis
3.1.1 Introduction to Survival Analysis
Survival analysis aims to estimate the three survival (survivorship, density, and haz-
ard) functions, denoted by S(t), f(t) and h(t), respectively (Collet, 1994). There
exist parametric as well as non-parametric methods for this purpose (Kleinbaum and
Klein, 2005). The survival function S(t) gives the probability of surviving beyond
time t, and is the complement of the cumulative distribution function, F (t). The
hazard function h(t) gives the instantaneous potential per unit time for the event to
occur, given that the individual has survived up to time t (Kleinbaum and Klein,
2005).
3.1.2 Censored Data
In survival analysis, one must consider censored data. This is a key issue for
the analysis of survival data and one of the reasons why survival analysis is a
17
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special topic within statistics. The difference between survival analyses with other
statistical analysis is the presence of censored data. In essence, censoring occurs
when there are some information about individual survival time, but the survival
time is unknown exactly.
According to Miller (1998) and Hougaard (2000) data are said to be censored if
the observation time censored survival is only partial, not until the failure event. One
major reason for this is that the person studied is alive when the data are evaluated,
and thus the complete lifetime is not known at that time.
There are many other reasons for censoring. For examples, the patients can be
lost to follow-up, patients still alive at the end of the study or patients drop out
of the study. There are also several types of censoring, including right censoring,
left censoring, interval censoring, random censoring, Type I censoring and Type II
censoring (Collet, 1994, Hosmer and Lemeshow, 1999, Kalbfleisch and Prentice,
2002, Kleinbaum and Klein, 2005). Right censoring occurs when a subject leaves
the study before an event occurs, or the study ends before the event has occurs
(Kleinbaum and Klein, 2005). Left censoring occurs when the event of interest
has already occurred before enrollment (Collet, 1994). Interval censoring occurs
when the survival time of each subject is only known to be within an interval (Sinha
et al., 1999). Random censoring occurs when each subject has a censoring time that
is statistically independent of their failure time (Kalbfleisch and Prentice, 2002).
Type I censoring occurs when an experiment has a set number of subjects and stops
at a predetermined time, at which point any subjects remaining are right censored
(Kalbfleisch and Prentice, 2002). Meanwhile, Type II censoring occurs when an
experiment has a set number of subjects and stops when a predetermined number are
observed to have failed; the remaining subjects are then right censored (Kalbfleisch
and Prentice, 2002).
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3.1.3 Characteristics of Survival Time Data
Survival time data have two important special characteristics (Kleinbaum and Klein,
2005) as follows:
• Survival times are non-negative, and consequently are usually positively skewed.
However, we can adopt a more satisfactory approach as an alternative distri-
butional model for the original data.
• Typically, some subjects (as mentioned above) have censored survival times.
There are nonparametric and parametric approaches to modelling survival data.
Some of these approaches are outlined now.
3.1.4 Kaplan-Meier
Kaplan-Meier procedure is an important and widely used tool in survival analysis
in dealing with censored data. It is a method for time to event data at each time
point when a particular event takes place. The Kaplan-Meier curves have become
the standard method of displaying time to event data (Royston et al., 2008). The
Kaplan-Meier method (Kaplan and Meier, 1958), also known as the product limit
estimator, which can be used to estimate the survival function from life time data.
By using this method, we can make comparisons of the survival (or failure) rates
between two or more groups in order to see either the effect of particular treatments
on the survival time of the patients (Royston et al., 2008) or to show the survivor
function risk groups (Kaderali et al., 2006, Rosenwald et al., 2002).
To estimate the survivor function without covariates, we can use the Kaplan-
Meier estimator. This method does not rely on distributional assumptions (dis-
tribution free method). Therefore, the Kaplan-Meier estimator is categorized as
a nonparametric technique (Collet, 1994, Kaplan and Meier, 1958). Given this
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property, we can use the Kaplan-Meier estimator to describe many forms of the
survivor function, S(t).
Let there be n individuals with observed survival times t1, . . . , tn and r be death
times amongst the individuals, where r ≤ n, j = 1, 2, . . . , r. The r ordered death
times are t(1) < t(2) < . . . < t(r). Let nj denotes the number of individual who are
alive just before time t(j) , including those who are about to die at this time, and let
dj denotes the number who die at this time.
We suppose now to make the assumption that the death of the individuals in the
sample occur independently of one another. Then, the estimated survival function
at any time in the kth constructed time interval from t(k) to t(k+1), k = 1, 2, . . . , r,
where t(r+1) is defined to be∞ and it estimates probability of surviving beyond t(k).
The Kaplan-Meier estimator of the survivor function (Collet, 1994) is given by
Sˆ(t) =
k∏
j=1
(
nj − dj
nj
)
.
The Kaplan-Meier estimator plot of the survivor function is like a step-function.
The estimated survival probabilities are constant between adjacent death times and
decrease at each death time (Collet, 1994).
3.1.5 Cox Proportional Hazard
A Cox proportional hazards (PH) model is a popular mathematical model used for
modelling survival. This model was proposed by Cox and Oakes (1972) and has
also come to be known as the Cox regression model. The reason why the Cox PH
model is so popular, is that because it is a semiparametric and a “robust” model.
The results from using this model will closely approximate the results of the correct
parametric model (Kleinbaum and Klein, 2005).
A survival analysis typically examines the relationship of the survival distri-
bution to covariates. If the risk of failure at a given time depends on the value
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of x1, x2, . . . , xp of p predictor variables X1, X2, . . . , Xp, then the value of these
variables are assumed to have the time origin. If h0(t) is the hazard function for
each object with the value of all predictor variable X is zero, then the function of
h0(t) are the baseline hazard function (Collet, 1994). The Cox PH model is usually
written in terms of the hazard model as follows
h(t) = h0(t) exp(β1X1 + β2X2 + . . .+ βpXp). (3.1)
There are two basic assumptions of this model; the effect of X is linear and β
is constant over time. The latter being the assumption of a proportional hazards.
It is also assumed that individuals are independent and homogeneous given their
covariates (Andersen, 1991).
An important feature of equation 3.1, which concerns the PH assumption, is that
the baseline hazard is a function of t, but does not involve the X’s (Kleinbaum and
Klein, 2005). In contrast, the exponential expression shown here, involves the X’s,
but does not involve t. Then, X’s here are called time independent X’s. Another
important property of the Cox model is that the baseline hazard, h0(t), can be an
unspecified function. This property that makes the Cox PH model a semiparametric
model (Hosmer and Lemeshow, 1999, Kleinbaum and Klein, 2005). In contrast, a
parametric model is one whose functional form is completely specified, except for
the values of the unknown parameters. For example, the Weibull PH model.
3.1.6 Frailty Model
The Cox proportional hazards (PH) model can be extended to allow time dependent
variables as predictors (Kleinbaum and Klein, 2005). Frailty models are extensions
of the PH model which is an known as the Cox model (Cox and Oakes, 1972).
The aim of this model is to account for unobserved heterogeneity that is caused by
22 CHAPTER 3. REVIEW OF STATISTICAL METHODS
unmeasured covariates (Hougaard, 1995). In statistical terms, a frailty model is a
random effect model for time to event data, where the random effect (the frailty)
has a multiplicative effect on the baseline hazard function (Duchateau and Janssen,
2008). Conditional on the frailty, the survival times are assumed to be independent
with PH structure. The modeling process is then completed by assuming multilevel
frailty effects (Kima and Dey, 2008).
3.1.7 Parametric Survival Model
A parametric survival model is one in which survival time (the outcome) is as-
sumed to follow a known distribution (Hosmer and Lemeshow, 1999, Kleinbaum
and Klein, 2005). The distributions that are commonly used for survival time are;
the Weibull (Collet, 1994, Ibrahim et al., 2001b), the exponential (a special case
of the Weibull) (Collet, 1994, Ibrahim et al., 2001b, Sparling et al., 2006), the log-
logistic, the log-normal, and the generalized gamma (Ibrahim et al., 2001b).
Survival estimates were obtained from parametric survival models typically
yield plots more consistent with a theoretical survival curve. If the investigator
is comfortable with the underlying distributional assumption, then the parameters
can be estimated and the survival and hazard functions can be specified as well
(Kleinbaum and Klein, 2005). This simplicity and completeness of a parametric
approach makes statistical tests more powerful.
For parametric survival models, time to event is assumed to follow certain dis-
tribution whose probability density function (pdf) f(t) can be expressed in terms of
unknown parameters (Collet, 1994). Once a probability density function is specified
for survival time, the corresponding survival and hazard functions can be deter-
mined.
Survival methods using the Bayesian statistical framework have been collated
more recently in the well regarded texts of Gelman et al. (2004), Ibrahim et al.
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(2001b) and Congdon (2006), with expanded applications in Congdon (2003).
3.2 Bayesian Modelling
3.2.1 Overview of Bayesian Approach
Modern Bayesian analysis began with a posthumous publication in 1763 by Rev-
erend Thomas Bayes that set the theoretical framework and after a status of around
200 years, publications by Geman and Geman (1984) and Bernando and Smith
(1994), among others, exploited computer technology and computational algorithms,
and extended the modelling framework.
The idea of Bayesian statistics within the context of life data analysis is to
integrate prior knowledge, along with a given set of current observations, in order
to make statistical inferences. The prior information could come from operational
or observational data, from previous comparable experiments or from engineering
knowledge (Gelman et al., 2004). This type of analysis can be mainly useful when
there is limited test data for a given design. By integrating prior information about
the parameters, a posterior distribution for the parameters can be obtained and
inferences on the model parameters and their functions can be made.
Suppose θ is some quantity that is unknown and let p(θ) denote the prior distri-
bution of θ. Next, let y be some observed data, whose probability of occurrence is
assumed to depend on θ. This dependence is formalized by p(y | θ), the conditional
probability of y for each possible value of θ, and when considered as a function of θ
is known as the likelihood (Spiegelhalter et al., 2004). The probability for different
values of θ, taking account of y is denoted by p(θ | y).
Bayes’ theorem applied to a general quantity says that:
p(θ | y) = p(y | θ)p(θ)
p(y)
.
Here, p(y) is
∫
p(θ | y)dθ and is considered as normalising factor to ensure that
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∫
p(θ | y)dθ = 1, so that
p(θ | y) ∝ p(y | θ)p(θ),
which says that the posterior distribution is proportional to the product of the likeli-
hood and the prior (Gelman et al., 2004, p.7-9).
The main differences between classical statistical inference and Bayesian statis-
tical inference is shown in Table 3.1 (Gelman, 2008).
Table 3.1: The difference between classical and Bayesian statistical inference.
Characteristics Classical Bayesian
Parameter of interest Unknown constant Random variable
Point estimate MLE Mean, mode or median of
posterior distribution
Interval estimate Confidence interval Credible interval
Quality of inference More restrictive than Bayes Depends on ability to
quantitatively relate past
experience to the
sample data
3.3 Prior Distribution
Prior distributions play a very important role in Bayesian statistics. There are
two different types of prior distributions; informative and non-informative (Gelman
et al., 2004, Marin and Robert, 2007, Spiegelhalter et al., 2004). Non-informative
prior distributions (vague, flat, and diffuse) play a minimal role in posterior in-
ference, and posterior can be sensitive to prior (Gelman et al., 2004). The non-
informative prior distributions can be used to make inferences that are not greatly
affected by external information or when external information is not available (Gel-
man et al., 2004, Marin and Robert, 2007, Spiegelhalter et al., 2004).
Informative priors have a stronger influence on the posterior distribution. The
influence of the prior distribution on the posterior is related to the relative variance
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of the data and the prior. We can obtained informative priors from past data or
expert information (Gelman et al., 2004, Marin and Robert, 2007, Spiegelhalter
et al., 2004).
Other categorisations of prior include conjugate prior, proper prior and improper
prior (Jeffreys prior) (Gelman et al., 2004, Marin and Robert, 2007, Spiegelhalter
et al., 2004). Several papers have been published on Bayesian survival analysis that
consider some very general constructions and applications of reference priors, other
than the normal prior. Among these are critical issues in Ibrahim and Laud (1991),
who examine Jeffreys’s prior for class of generalized linear models and Kim and
Ibrahim (2000) who discusses non-informative priors for linear combinations of the
means under the normal population. Other scholars, Berger and Bernardo (1989),
have examined reference priors for estimating a product of means. Bernardo (1997),
specifically, examines the existence of non-informative priors.
Bayesian methods provide a practical and effective tool for microarray analysis
(Baldi and Long, 2001, Gottardo, 2003, Ibrahim et al., 2002, Lewin et al., 2005).
The DNA microarray technology has important applications in gene expression data
analysis. However, the potential sources of random and systematic measurement er-
rors are a critical issue in statistical analysis. It is impossible to propose a statistical
model that reflects all sources of errors. Therefore, a good model should capture
the most essential features of the data.
3.4 Bayesian Computation
Bayesian computation generally exploits modern computer power to carry out simu-
lations (Spiegelhalter et al., 2004) based on Markov chains and is known as Markov
chain Monte Carlo (MCMC). Monte Carlo methods are techniques that have the aim
of evaluating integrals rather than exact or approximate algebraic analysis (Spiegel-
halter et al., 2004). Several MCMC algorithms that are commonly used are Gibbs
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sampling, Metropolis-Hastings, reversible jump, slice sampling, particle filters, per-
fect sampling and adaptive rejection sampling (Marin and Robert, 2007, Spiegelhal-
ter et al., 2004).
Three MCMC algorithms will be used in this research, namely Gibbs sampling,
Metropolis-Hastings and slice sampling. Gibbs sampling is an algorithm to generate
a sequence of samples from the joint probability distribution of two or more random
variables, with the purpose of approximating the joint distribution. Gibbs sampling
is applicable when the joint distribution is not known explicitly, but the conditional
distribution of each variable is known (Gelman et al., 2004). Moreover, the Gibbs
sampling algorithm is a method to generate an instance from the distribution of each
variable in turn, conditional on the current values of the other variables (Gelman
et al., 2004). Meanwhile, the Metropolis-Hastings algorithm is a rejection sampling
algorithm used to generate a sequence of samples from a probability distribution
that is difficult to sample from directly. This sequence can be used in MCMC
simulation to approximate the distribution, or to compute an integral (such as an
expected value) (Hastings, 1970). The Gibbs sampling algorithm is a special case
of the Metropolis-Hastings algorithm which is usually faster and easier to use but is
less generally applicable (Chib and Greenberg, 1995).
Furthermore, Neal (2003) described a class of “slice sampling” methods that can
be applied to sample from a wide variety of distributions. “slice sampling” is a type
of MCMC algorithm for drawing random samples from a statistical distribution.
The method is based on the observation that to sample a random variable one can
sample uniformly from the region under the graph of its density function (Damien
et al., 1999, Mira and Tierney, 2002, Neal, 2003, Tibbits et al., 2011). Simple forms
of univariate slice sampling are an alternative to Gibbs sampling that avoids the
need to sample from nonstandard distributions (Neal, 2003).
There are a vast number of published MCMC analyses, many of them using
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hand-tailored sampling programs. However, the WinBUGS software is widely used
in a variety of applications (Marin and Robert, 2007).
3.4.1 Weibull and Mixture Survival Models
Weibull Model
The Weibull model is perhaps the most widely used parametric survival model
in reliability (Kim and Ibrahim, 2000, Murthy et al., 2004) to characterize the
probabilistic behaviour of a large number of real world phenomena (Kaminskiy and
Krivtsov, 2005). A detailed review of the Weibull model can be found in Murthy
et al. (2004). Because of its various shapes of the probability density function (pdf)
and its convenient representation of the distribution/ survival function, the Weibull
distribution has been used very effectively for analyzing lifetime data, particularly
when the data are censored, which is very common in most life testing experiments
(Collet, 1994, Kundu, 2008).
Suppose we have independent identically distributed (i.i.d) survival times t =
(t1, t2, . . . , tn)
′, which follow a Weibull distribution, denoted by W (α, γ) with a
shape parameter α and a scale parameter γ. The parameter α represents the failure
rate behavior. If α < 1, the failure rate decreases with time; if α > 1, the failure
rate increases with time; when α = 1, the failure rate is constant over time, which
indicates an exponential distribution. The parameter γ has the same units as t, such
as years, hours, etc. A change in γ has the same effect on the distribution as a change
of the abscissa scale. Increasing the value of γ while holding α = 1 constant has
the effect of stretching out the pdf. If γ is increased, the distribution is stretched to
the right and its height decreases, while maintaining its shape. If γ is decreased, the
distribution is pushed in towards the left and its height increases (Figures 3.1 and
3.2) (Rinne, 2008, p.27-43).
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Figure 3.1: Weibull failure distribution with differing parameter values.
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Figure 3.2: Weibull densities with different values of the shape parameter.
The density function for Weibull distributed survival times is as follows:
f(ti | α, γ) =
αγt
α−1
i exp(−γtαi ), ti > 0, α > 0, γ > 0
0, otherwise.
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Since the logarithm of the Weibull hazard is a linear function of the logarithm
of time, it is more convenient to write the model in terms of the parameterization
λ = log(γ) (Ibrahim et al., 2001b), so that:
f(ti | α, λ) = αtα−1i exp(λ− exp(λ)tαi )
The corresponding survival function and the hazard function, using the λ pa-
rameterization, are as follows:
S(ti | α, λ) = exp(− exp(λ)tαi ),
h(ti | α, λ) = f(ti | α, λ)/S(ti | α, λ) = α exp(λ)tα−1i .
The likelihood function of (α, λ) is as follows:
L(α, λ | D) =
n∏
i=1
f(ti | α, λ)δiS(ti | α, λ)(1−δi)
= αd exp{dλ+
n∑
i=1
(δi(α− 1) log(ti)− exp(λ)tαi )},
where D = (t, δ) , d =
∑n
i δi and δi as follows
δi =
1, if the lifetime is uncensored, i.e., Ti = ti.0, if the lifetime is censored, i.e., Ti > ti.
Let xij be the jth covariate associated with ti for j = 1, 2, . . . , p + 1. The
covariate data can be included into the model through λ. Given that λ must be
positive, one option is to include the covariates as follows:
γi = exp(x
′
iβ), so that
λi = log(γi) = x
′
iβ, (3.2)
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where β = (β1, β2, . . . , βp) is the vector of regression parameter.
Thus, the log-likelihood function becomes:
logL(α,β | D) =
n∑
i=1
δi
(
log(α) + (α− 1) log(ti)
+ x′iβ
)− exp(x′iβ)tαi .
We can also extend equation (3.2) to include additional variation, i, perhaps
due to explanatory variables that are not included in the model. In this case, we
obtain:
λi = x
′
iβ + i, (3.3)
where i ∼ N(0, σ2).
Bayesian Weibull Model
Prior information might include one or more of the model parameters. The integra-
tion of such prior information into model (3.1) could be expressed in the form of
a probability density, p(θ, β|H), where H represents the background information.
This prior density is then combined with the observed data, in the form of the like-
lihood, using Bayes’ Theorem. Thus, the posterior joint density, p(θ, β|H, data), is
proportional to the product of the likelihood and the prior density, p(θ, β|H).
In a microarray setting, one of the regression parameters may represent a gene
expression, about which there will be prior information available (Kaderali et al.,
2006, Tachmazidou et al., 2008). This may take either the expert belief or the results
from the analysis of similar studies.
In a complex model, the posterior densities can often be too difficult to work
with directly (Bolstad, 2010, Ibrahim et al., 2001b, Omurlu et al., 2009). To update
knowledge about the parameters requires that one can sample from the posterior
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density. With MCMC methods, it is possible to generate samples from a posterior
density and to use these samples to approximate expectations of quantities of in-
terest. MCMC method samples successively from a target distribution, with each
sample drawn depending on the previous one (see Section 3.4).
Some papers have appeared on the Bayesian approach to Weibull survival mod-
elling. Among these are Abrams et al. (1996) who analyzed parametric propor-
tional hazards models in clinical data. Kostoulas et al. (2010) examined a Bayesian
Weibull survival model for time to infection data measured with delay, and Kundu
(2008) also analysed the Bayesian inference of unknown parameters of the progres-
sively censored Weibull distribution. Other scholars, Ahmed et al. (2010) analysed
the comparison of the Bayesian and maximum likelihood estimation for Weibull
distribution and Kaminskiy and Krivtsov (2005) proposed a simple procedure for
Bayesian estimation of the Weibull distribution. However, the literature on Bayesian
survival is still growing and there is limited literature to date on Bayesian survival
modelling using gene expression and consider model choice issues and sensitivity
analysis, e.g. Weibull model.
Under the assumptions stated in Section 3.4.1, a Bayesian formulation of the
Weibull model takes the form
ti ∼ W (ti | α, λ), i = 1, 2, ..., n.
α ∼ p(α | θα).
λ ∼ p(λ | θλ),
where θα and θλ are the hyperparameters of the prior distribution of α and λ, re-
spectively. In this model, inference may initially focus on the posterior distribution
of the shape parameters α and the scale parameter λ.
Combining the likelihood function of (α, λ) with the prior distributions, the joint
32 CHAPTER 3. REVIEW OF STATISTICAL METHODS
posterior distribution of (α, λ) is given by
p(α, λ | D) ∝ L(α, λ | D)p(α)p(λ).
Since the joint posterior distribution of (α, λ | D) does not have a closed form,
we use MCMC methods for computation (Gilks et al., 1996). Given the conditional
distributions defined in Algorithm 1, the conditional distribution of λ does not have
an explicit form.
Algorithm 1 Weibull survival model without covariates
1: k = 0, Set initial values [α0, λ0]
For k = 1 : K, where K is large,
2: Sample α(t+0) ∼ α | λ(t), D, for i = 1, 2, ..., n
3: Sample λ(t+0) ∼ λ | α(t), D, for i = 1, 2, ..., n
4: Set k = k + 1 and go to step 1
5: Continue required number of iterations
6: Stop
In order to build a Weibull model with covariates, we develop a hierarchical
model, introducing the covariates xi through λ using the equation (3.3).
The joint posterior distribution of (α,β) is given by
p(β, α | D) ∝ L(α,β | D)p(α)p(β)
MCMC analysis is done using the conditional distributions of the parameters,
as described in Algorithm 2. As discussed earlier, the conditional distribution of
α does not have an explicit form and as such can be sampled from approximately
algorithms such as Metropolis-Hastings or slice sampling (Gilks et al., 1996).
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Algorithm 2 Weibull survival model with covariates
1: k = 0, Set initial values [α0, β0]
For k = 1 : K, where K is large,
2: Sample α(t+0) ∼ α | β(t), D, for i = 1, 2, ..., n
3: Sample β(t+0) ∼ λ | α(t), D, for i = 1, 2, ..., n
4: Set k = k + 1 and go to step 1
5: Continue required number of iterations
6: Stop
3.4.2 Mixture Weibull Models
In many cases, the application of a single parametric distribution is not sufficient to
describe the complexity of the data being observed. For instance, the data may have
been generated from several (possibly uncensored) homogenous subgroups. To
produce an appropriate inference, these groups should be taken into consideration.
Mixture models are usually used in modelling data consisting of several groups,
where each group has different properties and characteristics of the one family but
use the same distribution. This model provides a convenient and flexible mechanism
for identification and estimation of distributions which are not well modelled by
any standard parametric family (Stephens, 1997). This is achieved by assuming
that the observed data can be represented by a weighted sum of distributions, with
each distribution defined by a unique parameter set representing a subspace of the
population.
Weibull mixture models have received increasing attention in recent statistical
research with applications in the field of survival and reliability analysis. The
advances in EM algorithm (Dempster et al., 1977), the Bayesian paradigm (Berger,
1985), (Besag et al., 1995), and MCMC computational methods (Diebolt and Robert,
1994) have substantially expanded the methodology and application of Weibull mix-
ture models. For example, in the Bayesian context, Marin et al. (2005a) described
methods to fit a Weibull mixture model with an unknown number of components.
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Chen et al. (1985) used a two component mixture model for the analysis of cancer
survival data, generalizing an earlier idea by Berkson and Gage (1952). Similarly,
Farcomeni and Nardi (2010) proposed a two component mixture to describe survival
times after an invasive treatment. Qian (1994) also used a mixture of a Weibull
component and a surviving fraction in the context of a lung cancer clinical trial.
Tsionas (2002) considered a finite mixture of Weibull distributions with a larger
number of components for capturing the form of a particular survival function.
There is developing literature for fitting mixture models to censored data. For
example, Miyata (2011) used the maximum likelihood estimator for fitting a mix-
ture of exponential distributions and a mixture of normal distributions with censored
data, and Hanson (2006) modelled censored lifetime data using a mixture of gam-
mas. An overview can be found in Ibrahim et al. (2001b). However, there is limited
attention to Bayesian mixture models in the field of survival analysis, e.g. Weibull
mixture and limited attention to the effect of censoring on the mixture.
Initially, we assume that we observe survival time t on patients possibly from a
heterogeneous population. As in Section 3.4.1, the two parameter Weibull density
function for survival time is given by
W (t | α, γ) = αγtα−1 exp (−γtα) ,
for α > 0 and γ > 0, where α is a shape parameter and γ is a scale parameter
(Ibrahim et al., 2001b). A mixture of K Weibull densities is defined by (Marin
et al., 2005a)
f(t | K,pi,α,γ) =
K∑
m=1
pimW (t | αm, γm), (3.4)
where α = (α1, . . . , αK), γ = (γ1, . . . , γK), are the parameters of each Weibull
distribution and pi = (pi1, . . . , piK) is a vector of nonnegative weights that sum to
one.
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The corresponding survival function S(t | K,pi,α,γ) and hazard function h(t |
K,pi,α,γ) are as follows
S(t | K,pi,α,γ) =
K∑
m=1
pim exp (−γmtαm) ,
h(t | K,pi,α,γ) = f(t | K,pi,α,γ)/S(t | K,pi,α,γ).
Let xij be the jth covariate associated with patient i, for j = 1, 2, . . . , p. The
covariates can be included in the model as follows (Farcomeni and Nardi, 2010)
log(γm) = x
′
iβm = λm, (3.5)
where xi = (xi1, . . . , xip), γm = (γ1m, . . . , γpm) and βm = (β1m, . . . , βpm), for
i = 1, 2, . . . , n and m = 1, 2, . . . , K.
We now assume that we observe possibly right censored data for n patients;
y = (y1, . . . , yn) where yi = (ti, δi) and δi is an indicator function (Marin et al.,
2005a) such that
δi =
1, if the lifetime is uncensored, i.e., Ti = ti.0, if the lifetime is censored, i.e., Ti > ti.
Thus, the likelihood function becomes
L (pi,α,γ | K, ti, δi,x) ∝
n∏
i=1
f (ti | K,pi,α,γ,x)δi S (ti | K,pi,α,γ,x)1−δi .
Here, the incomplete information is modelled via the survivor function, which
reflects the probability that the patient was alive for duration greater than ti.
Bayesian Mixture Weibull Models
In WinBUGS (Lunn et al., 2000, Ntzoufras, 2009, Spiegelhalter et al., 2002), pos-
sibly right censored data can be modelled using a missing data approach via the
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command I(., ) as follows
t[i] ∼ dweib(alpha[i], gamma[i])I(cens.time[i], )
where cens.time[i] is either zero for uncensored outcome or the ith recorded sur-
vival time for censored outcomes. Hence, censored survival times are assumed to
be drawn from a truncated Weibull distribution.
The following prior distributions were placed on the parameters pi and α:
pi | K ∼ Dirichlet(φ1, . . . , φK), φm = φ,∀m = 1, 2, . . . , K.
αm ∼ Gamma(uα, vα),m = 1, 2, . . . , K.
For a model without covariates, we employ the Gamma prior and for a model
with covariates, we employ an independent normal prior on each βm.
The model described in Section 3.4.2 can be fitted using MCMC sampling with
latent values Zi to indicate component membership of the ith observation (Diebolt
and Robert, 1994), (Robert and Casella, 2000). Since pim = Pr(Zi = m), we
can write Zi ∼ M(pi1, . . . , piK). In this scheme, the Zi are sampled by computing
posterior probabilities of membership, and the other parameters are sampled from
their full posterior distributions, conditional on the latent indicators.
Label switching is a known problem in mixture model analysis. The problem
arises from the invariance of the likelihood with respect to the permutations of the
component labels in the mixture model (Marin et al., 2005b, Mengersen et al.,
2011, Stephens, 2000a). As a result, the marginal distributions of the parameters
are identical for all components and the posterior expectations for the parameters
are also identical.
There exist a number of alternative approaches in the literature that could have
been used. Green (1995) proposed a new framework for the construction of re-
versible Markov chain samplers that jump between parameter subspaces of dif-
fering dimensionality, which is flexible and entirely constructive. Following this,
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Stephens (2000a) proposed an alternative of reversible jump methods for dealing
with Bayesian analysis of mixture models with unknown number of components.
Stephens (2000b) and Celeux et al. (2000) also describe an alternative approach,
called relabelling algorithms, that involve the minimisation of the posterior expected
loss under a class of loss functions. Fruhwirth-Schnatter (2000) proposed “permu-
tation MCMC”, as means of choosing prior constraints to reduce the occurrence
of label switching. A detailed review of these approaches and others features in
Jasra et al. (2005). Label switching, caused by non-identifiability of the mixture
components, was dealt with post-MCMC using the reordering algorithm of Marin
et al. (2005b). More recently, Roodaki et al. (2013) addressed the problems of
relabeling and summarising posterior distributions that typically arise when dealing
with signal decomposition problems with an unknown number of components.
3.4.3 Cure Models
The cure rate model is defined in this section. Models for survival analysis typically
assume that everybody in the study population is susceptible to the event of interest
and will eventually experience this event if the follow-up is sufficiently long. In
recent years, there has been increasing interest in modelling survivor data with long
term survivors. Most approaches to the analysis of time to event data implicitly
assume all individuals will experience the event of interest. However, there are
situations when a proportion of individuals are not expected to experience the event
of interest; that is, those individuals are often referred to as immune, cured or non-
susceptible (Ibrahim et al., 2001b). For example, researchers may be interested
in analysing the recurrence of disease. Many individuals may never experience a
recurrence. In these situations, cure rate models are applied.
The most popular type of cure rate models introduced by Berkson and Gage
(1952) with the earlier work included Boag (1949), is the mixture model, which
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is also called the standard cure rate model. Let S1(t) be the survivor function for
the entire population, S∗(t) be the survivor function for the non-cured group in the
population, and pi be the cure rate function. Then the standard cure rate model is
given by
S1(t) = pi + (1− pi)S∗(t). (3.6)
Exponential and Weibull distributions are commonly used for S∗(t). This model
has been extensively discussed in the statistical literature by many authors. A
detailed review of the cure model can be found in the books by Maller and Zhou
(1996, p.97-223) and Ibrahim et al. (2001b, p.155-205). In frequentist context
for parametric models, Farewell (1986) examined mixture models and advocated
the likelihood function as an informative inference tool to estimate the fraction of
patients cured of breast cancer disease. Farewell (1986) also suggested that the cure
rate models in a clinical setting would only be sensible if the data are based on long
term follow-up. Peng and Xu (2012) proposed a novel interpretation for a recently
proposed Box-Cox transformation cure model for colon cancer, which leads to a
natural extension of the cure model. An alternative formulation of the parametric
cure rate model is discussed in Yakovlev and Tsodikov (1996). In Bayesian context,
Chen et al. (1985) generalised the mixture model of Berkson and Gage (1952) and
used for the analysis of survival data from cancer. Chen et al. (1999) considered
Bayesian methods for right censored survival data for populations with a cure frac-
tion and proposed a model that is quite different from the standard mixture model for
cure rates. Basu and Tiwari (2010) developed a model that unifies the mixture cure
and competing risks approaches and that can handle the masked causes of death
from breast cancer in natural way by using Markov chain sampling. Moreover,
Cancho et al. (2011) discussed the use of MCMC methods as a reasonable way to
get Bayesian inference for analysis of survival data with a cure rate by proposing the
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negative binomial distribution as an extension of the model presented in Chen et al.
(1999). Cancho et al. (2012) developed a Bayesian analysis for the right censored
survival data when cured individuals may be present in the population from which
the data are taken by using MCMC method.
There have been various applications of the mixture cure model. Angelis et al.
(2007) analysed the survival of colon cancer patients by adjusting for background
mortality. Simonetti et al. (2008) applied the mixture cure model to estimate the
complete prevalence of childhood cancer. Chen et al. (2002) developed and com-
pared three Bayesian models (piecewise exponential model, a fully parametric cure
rate model and a semiparametric cure rate model) for analyzing time to event data
for high risk melanoma. Beside the parametric mixture cure models, there are
a number of semiparametric mixture cure models in the literature, for example,
semiparametric estimation procedures by using the proportion time cure model
(Chen et al., 1999, Ibrahim et al., 2001a, Kim et al., 2007), the proportional haz-
ards mixture cure model (Peng and Dear, 2000), (Goldman, 2000), the accelerated
failure time mixture cure model (Peng and Dear, 2009, Zhang and Peng, 2007,
Zhang et al., 2011). The mixture cure model has also been implemented in several
statistical packages. Peng et al. (1998) developed an R package GFCURE and
Corbiere and Joly (2007) provided a SAS macro for parametric and semiparametric
mixture cure model. The CANSURV (Yu et al., 2005) of the National Cancer
Institute (NCI) fits mixture cure models to population based cancer survival data
using maximum likelihood method.
As in Yakovlev and Tsodikov (1996), Chen et al. (1999) and Ibrahim et al.
(2001b), for an individual in a population, let N denote the number of latent vari-
ables. Assume that N has a Poisson distribution with mean θ. Let Zi, i = 1, . . . , N
denote the random time, where Zi are i.i.d. with a distribution function F (t) =
1 − S(t). Also, assume that Zi are independent of N . The time to event can be
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defined by the random variable Y = min(Zi, 0 ≤ i ≤ N), where P (Z0 =∞) = 1.
Hence, the survival function for the population is given by
Spop(t) = P (N = 0) + P (Z1 > t, . . . , ZN > t,N ≥ 1)
= exp(−θ) +
∞∑
k=1
[S(t)]k
θk
k!
exp(−θ)
= exp(−θF (t)). (3.7)
A corresponding cure fraction in model (3.7) is limt→∞ Spop(t) = exp(−θ) > 0.
We also know from (3.7) that the cure fraction is given by Spop(∞) = P (N = 0) =
exp(−θ). As θ → ∞, the cure fraction tends to 0, whereas as θ → 0, the cure
fraction tends to 1. Corresponding population density and hazard functions are
fpop(t) = − ddtSpop(t) = θf(t) exp(−θF (t)) and hpop(t) = θf(t), respectively.
The PH structure with the covariates is modelled through θ (Chen et al., 1999,
Ibrahim et al., 2001b). The population survival function (3.6) can be written as
Spop(t) = exp(−θ) + [1− exp(−θ)]S∗(t),
where S∗(t) = exp(−θF (t))−exp(−θ)
1−exp(−θ) , and f
∗(t) = exp(−θF (t))
1−exp(−θ) θf(t).
Following Chen et al. (1999) and Ibrahim et al. (2001b), we construct the like-
lihood function. Suppose we have n subjects and assume that N ′i s are i.i.d with
Poisson distributions with means θi, i = 1, . . . , n. Let Zi1, . . . , ZiNi denote the
times for the Ni competing causes, which are unobserved, and which have a cumu-
lative distribution function, F (.). In this section, we specify a parametric form for
F (.), for the Weibull distribution. Let ψ = (α, λ)′ , where α is the shape parameter
and λ is the scale parameter. We incorporate covariates for the cure rate model
through the cure parameter θ and we have a different cure rate parameter, θi, for
each subject.
Let x′i = (xi1, . . . , xik) denote the k x 1 vector of covariates for the ith subject,
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and let β = (β1, . . . , βk) denote the corresponding vector of regression coefficients.
We relate θ to the covariates by θi = exp(x
′
iβ). Let ti denote the survival time for
subject i, which is right censored, let Ci be the censoring time, and let δi be the
censoring indicator, assuming 1 if Ti is a failure time and 0 if it is right censored.
The observed data are D = (n, t, δ,X), where t = (t1, . . . , tn)
′ , δ = (δ1, . . . , δn)
′
and X = (x1, . . . , xn)
′ . The complete data are given by Dc = (n, t, δ,X,N ),
whereN = (N1, . . . , Nn)
′ . The complete-data likelihood function of the parameter
(ψ,β) can be written as
L(ψ,β | Dc) =
{
n∏
i=1
S(ti | ψ)Ni−δi(Nif(ti | ψ))δi
}
× exp
{
n∑
i=1
Ni log(θi)− log(Ni!)− nθi
}
. (3.8)
Again, we assume independent priors for β and ψ, where α ∼ Gamma(aα, bα),
λ ∼ N(µλ,Σλ) and β ∼ N(µβ,Σβ). We also assume p(α, λ) = p(α | δ0, τ0)p(λ),
p(α | δ0, τ0) ∝ αδ0−1 exp(−τ0α), and the hyperparameters (δ0, τ0) are specified
(Chen et al., 1999, Ibrahim et al., 2001b).
Combining these specifications with the likelihood function (3.8), the joint pos-
terior distribution of (α, λ,β) becomes
p(α, λ,β | D) ∝
n∏
i=1
(θif(ti | α, λ))δi exp(−θi(1− S(ti | α, λ)))
×p(α | δ0, τ0)p(α, λ)p(β). (3.9)
The joint posterior density of (α, λ,β) in equation (3.9) is analytically intractable
because the integration of the joint posterior density is not easy to perform. Hence,
inferences are based on MCMC simulation methods. We can use the Metropolis-
Hastings algorithms or slice sampling to simulate samples of α, λ and β. MCMC
computations were implemented using the WinBUGS system (Spiegelhalter et al.,
2002).
42 CHAPTER 3. REVIEW OF STATISTICAL METHODS
3.5 Bayesian Variable Selection
As indicated by some experts (e.g. Broman and Speed (2002), Sillanpaa and Coran-
der (2002)), the problem of deciding an optimal model from a set of a priori plausi-
ble models in statistical analysis has resulted in the use of a variety of algorithms for
investigating the model space and selection criteria for choosing between competing
models. According to O’Hara and Sillanpaa (2009), in the context of Bayesian
framework, the problem of model selection can be transformed to the form of pa-
rameter estimation. Moreover, they argue that a prediction of the marginal posterior
probability that a variable should be included in the model becomes the particular
objective of many studies.
The selection of variables in regression problems has occupied the minds of
many statisticians. Several Bayesian variable selection methods have been devel-
oped especially in microarray studies. For example, Bayesian variable selection
approaches can be used to identify the relevant markers by jointly assessing sets of
genes (Sha et al., 2004).
The main goal in applying survival analysis to microarray data is to determine
a highly predictive model of patients’ time to event (such as death, relapse, metas-
tasis) using a small number of selected genes. In the context of survival analysis,
a model refers to a set of selected genes whose regression coefficients have been
calculated for use in predicting survival prognosis (Volinsky et al., 1997).
Recently, a number of literature have applied survival analysis to microarray
data. Beer et al. (2002) used univariate Cox PH regression along with leave one-out
cross validation on an 86 sample lung cancer dataset to develop a risk index based on
50 genes that successfully divided an independent test set of patients into high and
low risk groups. Lu et al. (2006) improved on these results by using a multivariate
Cox PH model with bootstrap resampling and forward selection to obtain a 64 gene
3.5. BAYESIAN VARIABLE SELECTION 43
model that yielded a greater predictive accuracy than Beer et al. (2002).
A popular approach to deal with high dimensionality in survival analysis is
dimension reduction. For example, Bair and Tibshirani (2004) proposed a semi-
supervised version of principal components analysis that is capable of generating
a continuous predictor of patient survival. Their algorithm consistently selected
fewer than 20 genes and successfully divided patients into high and low risk groups
in four different cancer subtypes; lymphoma, breast cancer, lung cancer, and acute
myeloid leukemia.
Partial least square (PLS) is another technique to reduce the dimensionality of
the original variables by constructing a smaller collection of latent variables that
are linear combinations of the original variables (Nguyen and Rocke, 2002). The
application of PLS in conjunction with the Cox PH model in survival analysis to
microarray data has been investigated by Nguyen and Rocke (2002) and Li and Gui
(2004). A problem of dimension reduction techniques is that usually a relatively
large number of genes (variables) are selected in the reduced dimension space.
Lee (2004) proposed a hierarchical Bayesian model for gene selection by using
latent variables in a regression setting and a Bayesian mixture prior to perform the
variable selection. She also applied MCMC based stochastic research technique
with mainly Gibbs algorithm to obtain the posterior samples. Kaderali et al. (2006)
proposed a multivariate Cox regression model embedded in a Bayesian framework
that combines dimension reduction and regression in one single step. They used
a hierarchical prior distribution that is strongly peaked around zero on the regres-
sion parameters so as to produce a small number of relevant genes with non-zero
regression parameters. A distinctive characteristic of this method is that the authors
assume that the baseline hazard rate in the Cox proportional hazards model is
constant. Kaderali et al. (2006) have presented CASPAR, a new method to correlate
gene expression data with survival, based on a combination of the Cox regression
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model with a Bayesian “Automatic relevance determination” (ARD) approach.
Datta and Le-Rademacher (2007) investigated the performances of least abso-
lute shrinkage and selection operator (LASSO) and PLS on microarray data using
the AFT model. Through simulation studies, they showed that LASSO performed
better than PLS when there are many noisy variables in their simulation studies.
The selection of variables in regression problems has occupied the minds of
many statisticians. Several Bayesian variable selection methods have been applied
to gene expression and survival studies. For example, these approaches have been
used to identify relevant markers by jointly assessing sets of genes (Sha et al., 2006).
The problem of model selection is abundant throughout the literature. This
includes both covariate selection and choice of the model itself. Some of the meth-
ods are based on a series of significance tests while others fit more comprehensive
models; some include prior information; some use analytic or approximate methods
of estimation while others use Markov Chain Monte Carlo (MCMC) methods;
different approaches use different optimisation or model comparison criteria such
as Bayes factors (Raftery, 1996). For example, McGrory and Titterington (2007)
showed how variational techniques can be used to extend the deviance information
criterion (DIC) to include the comparison of mixture models, whilst Basu and
Tiwari (2010) used Bayes factors to compare the various model structures in breast
cancer survival data.
3.6 Sensitivity Analysis
Sensitivity analysis is today a crucial element in any practical decision analysis.
In such sensitivity analysis, we can apply robustness testing. Robustness testing is
an important part of Bayesian statistics, particularly in its application to real world
decision problems (O’Neill, 2009).
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The question of sensitivity should not be viewed as an afterthought. Berger
(1990) explained the situation as follows:
“There is a common perception that foundational arguments lead to subjective
Bayesian analysis as the only coherent method of behaviour. . . . Subjective
Bayesian analysis is, indeed, the only coherent mode of behaviour, but only if it
is assumed that one can make arbitrarily fine discriminations in judgement about
unknowns and utilities. . . . It is less well known that realistic foundational systems
exist, based on axiomatics of behaviour which acknowledge that arbitrarily fine
discrimination is impossible. . . . The conclusion of these foundational systems is
that a type of robust Bayesian analysis is the coherent behaviour. Roughly, coherent
behaviour corresponds to having classes of models, priors, and utilities, which
yield a range of possible Bayesian answers (corresponding to the answers obtained
through combination of all modelprior-utility triples from the classes). If this range
of answers is too large, the question of interest may not, of course, be settled, but
that is only realistic. . . (pp. 6-7, emphasis in original)”
In a decision analysis, it is standard practice to perform sensitivity analyses on
parameter estimates. This approach can be problematic if parameter estimates are
correlated or if model structure does not permit obvious standard error estimates
(Hazen and Huang, 2006). Both of these difficulties can occur when the analysis of
time to event data known as survival analysis plays a significant role in the decision
analysis (O’Neill, 2009).
Sometimes a controversial aspect of the Bayesian approach is the need to specify
prior distributions for the unknown parameters. In certain situations these priors
may be very well defined. However, for complex models with many parameters,
the choice of priors and conclusions of the subsequent Bayesian analysis are usually
validated through a prior sensitivity analysis (Nur et al., 2009). Varying the prior
distributions by applying normal prior, uniform prior etc can be used to assess the
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sensitivity of prior (Gelman et al., 2004, Qian, 1994). The sensitivity of the mea-
surement of expression levels (as they are always subject to measurement errors) can
be checked by adding Gaussian noises to the expression values (Lee, 2004). Nur
et al. (2009) used importance sampling to assess the sensitivity to prior specification
in Bayesian hidden Markov models for DNA sequence segmentation. O’Neil (2009)
also explained the use of importance sampling for Bayesian sensitivity analysis in
approximating the range of the imprecise previsions and develops an approximation
function for the imprecise posterior prevision based on generating a finite number
of random variables.
Sensitivity analysis of prior choice can also affect model choice and it can be
applied to for example cure model (Hazen and Huang, 2006) and mixture of Weibull
distributions (Mosler and Scheicher, 2008).
3.7 Goodness of fit
The appropriateness of the model can be checked by applying goodness of fit mea-
sures which summarize the discrepancy between observed values and the values
expected under the model in question (Gupta et al., 2008). The most commonly
used assessments of model fit are in the form of information criteria, such as the
Bayesian Information Criterion (BIC) (Schwarz, 1978a),
BIC = −2 logL(t | θ) + k log(n),
and the Deviance Information Criterion (DIC) (Spiegelhalter et al., 2002),
DIC = −2E(log(L(t | θ) | t)) + pD.
For BIC, θ are unknown parameters of the model, n is the number of uncensored ob-
servation in the survival context (Volinsky and Raftery, 2000), and k is the number
of free parameters in the model. The term k log(n) in the BIC is also a complexity
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measure. The DIC penalises complexity slightly differently through the term pD.
The term estimates the effective number of parameters as follows
pD = D(θ)−D(θ),
where D(θ) represents the mean deviance and D(θ) denotes the deviance at the
posterior means of the parameters. Both the BIC and DIC can be calculated from
the simulated values based on MCMC results; smaller values indicates a more
suitable model in terms of goodness of fit and short-term predictions (McGrory
and Titterington, 2007), (Spiegelhalter et al., 2002).
Volinsky and Raftery (2000) investigated the BIC for variable selection in mod-
els for censored survival data and Ibrahim et al. (2008) developed Bayesian method-
ology and computational algorithms for variable subset selection in Cox PH model
with missing covariate data. Other papers that deal with related aspects are Cai
and Meyer (2011) and Gu et al. (2011). Cai and Meyer (2011) used conditional
predictive ordinates and the DIC to compare the fit of hierarchical proportional
hazards regression models based on mixtures of B-spline distributions of various
degrees. Gu et al. (2011) presented a novel Bayesian method for model comparison
and assessment using survival data with a cured fraction.
Comparing the predictive distribution to the observed data is generally termed
a posterior predictive check (Gelman et al., 2004). If a model fits the data well, the
observed data should be relatively likely under the posterior predictive distribution.
In frequentist statistics, the chi-square test is the test most widely used for
assessing goodness of fit, at least for discrete models. In Bayesian approach, the
Bayes factor can be used to assess goodness of fit when no specific prior information
is available (Conigliani et al., 2000).
The other form of model evaluation which can be useful in simulation studies
is calculating the root mean squared error (RMSE) for each parameter. The RMSE
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is an indicator of the fit between the estimated and the true parameter values. A
smaller RMSE reflects a better model fit (Kenney and Keeping, 1962, Wackerly
et al., 2002).
3.8 Bayesian Model Averaging
A variety of methodologies exist to compare several competing models for a given
dataset and to select the one best fits the data. Bayesian model averaging (BMA) is
one way of combining models in order to account for the uncertainty. By averaging
over many different competing models, BMA incorporates model uncertainty in
inference and prediction. Draper (1995) and Raftery (1995) reviewed BMA and the
cost of ignoring model uncertainty. Madigan and Raftery (1994) also considered the
BMA by using Occam’s razor and Occam’s window approaches to reduce the num-
ber of candidate models. Yuan and Yin (2011) used model averaging procedures to
make more robust inferences regarding the dose finding design for phase I clinical
trials. Pramana et al. (2012) focused on the case in which several parametric models
are fitted to gene expression data and discussed model averaging techniques for the
estimation of the dose response model. See Hoeting et al. (1999) for a good tutorial
for BMA. There is a large literature on BMA. However, there is limited attention on
model uncertainty, e. g. a single Weibull, a mixture of Weibulls and a Weibull cure
model.
The key elements of BMA were discussed by Raftery (1995). He suggested
weighting each model by the posterior model probabilities derived from a Bayesian
analysis. Assume that there are S models being considered, for s = 1, 2, . . . , S,
each with parameter set θs based on data D.
Let ∆ be the quantity of interest; this could represent, for example, the posterior
predictive distribution of y. Hence, the posterior distribution of ∆ given data D
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(Hoeting et al., 1999) is
p(∆ | D) =
S∑
s=1
p(∆ | S = s,D)p(S = s | D)
where p(S = s | D) is the posterior probability of a particular model being true,
defined as
p(S = s | D) = p(D | S = s)p(S = s)∑S
s=1 p(D | S = s)p(S = s)
, s = 1, 2, . . . , S,
where p(D | S = s) = ∫ p(D | θs, S = s)p(θs | S = s)dθs
Here, p(D | S = s) is the marginal likelihood of the data D given model S and
p(θs | S = s) is the prior density of θs given model S = s. p(S = s) is the prior
probability for models being true (Hoeting et al., 1999).
Given a model selection problem in which we have to choose between two
models, the plausibility of the two different models S1 and S2 is assessed by the
Bayes factor as the ratio of posterior model probabilities.
The main detractor from using Bayes factors is that they are, in general, difficult
to compute. Raftery (1995) proposed using BIC (Schwarz, 1978b) as an approx-
imation. Buckland et al. (1997) and Claeskens and Hjort (2008) discussed the
utilization of BIC in Bayesian model averaging. Buckland et al. (1997) proposed
simpler methods where weights are based upon the penalized likelihood functions
formed from the AIC (Akaike, 1973).
The starting point for Burnham and Anderson’s model selection theory is the
Kullback-Leibler (KL) information given by Burnham and Anderson (2002) and
Claeskens and Hjort (2008):
I(f | q) =
∫
f(x) log
f(x)
q(x | θs)dx,
where f represents the density function of the true and unknown model, q represents
the density function of the model that is used to approximate f , and θs is a vector
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of the unknown parameters to be estimated. The notation I(f | q) denotes the
information lost when q is used to approximate f or the distance from q to f . For
a given set of models, one can compare the KL information for each model and
select the model that minimises the information loss across the considered set of
models (Burnham and Anderson, 2002), (Burnham and Anderson, 2004). How-
ever, in practice I(f | q) cannot be computed since the true model f is unknown.
Schwarz (1978b) and Burnham and Anderson (2002) made the link between the KL
information and likelihood theory and showed that the expected KL information can
be expressed as
E(KL) = − log p(D | θˆs, S = s) + ds log(n),
where p(D | θs) is the likelihood, ds is the number of parameters in the model
and n is the number of uncensored observations in a survival context (Volinsky and
Raftery, 2000).
A Laplace approximation, typically the Bayesian Information Criterion (BIC,
Schwarz (1978b)) can be used to approximate p(D | S = s) (Clyde, 2000, Hoeting
et al., 1999, Jackson et al., 2009, Yuan and Yin, 2011)
log (p(D | S = s) ≈ log p(D | θˆs, S = s)− ds log(n)
BIC = −2 log p(D | θˆs, S = s) + ds log(n).
Here log p(D | θˆs, S = s) is the maximised log-likelihood of model s, which
estimates goodness of fit of the data.
Schwarz (1978b) and Burnham and Anderson (2002) proposed the likelihood of
the model given the data, using θˆs defined by
p(D | θˆs, S = s) ∝ e0.5×BIC
The BMA weight for the sth model (Jackson et al., 2009, Yuan and Yin, 2011)
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is given by
p(S = s | D) = exp(−
1
2
BICs)p(S = s)∑S
s=1 exp(−12BICs)p(S = s)
,
The BMA weight can be interpreted as the weight of the evidence that model
s is the best model given a set of S models. For the case with non-informative
prior probabilities, we can let p(S = s) equal for all candidate models (1/S),
indicating no prior preference for any of the models (Jackson et al., 2009), (Pramana
et al., 2012). The model with the highest BMA weight will be considered as the
best model. Therefore, p(S = s | D) is also an approximation to the posterior
probability of the model s being correct (Schwarz, 1978b). A smaller BIC values
indicates a better model fit, accounting for model parsimony.
Let f˜sj be the jth simulated observation from the sth model. Then, the mean of
survival from the BMA model (f¯MA), can be calculated as follows
f¯MA =
(
N∑
j=1
S∑
s=1
wsf˜sj
)
/N,
where N is the number of simulated observation and ws = p(S = s | D) is the
BMA weight, defined previously.
Annest et al. (2009) extended the implementation of BMA method to survival
analysis of high-dimensional microarray data to select a small number of predic-
tor genes while providing greater predictive accuracy. In particular, Annest et al.
(2009) developed and implemented the iterative BMA method (Hoeting et al., 1999,
Raftery, 1995, Yeung et al., 2005) for survival analysis as a Bioconductor package.
There are some approaches to calculate the marginal likelihood p(D | S =
s). For example, the harmonic mean estimator (Newton and Raftery, 1994), a
generic method which can be applied to output from the Gibbs sampler (Chib’s
method) (Chib and Greenberg, 1995), Annealed importance sampling (AIS) (Neal,
2001), nested sampling (Skilling, 2006), power posterior (Friel and Pettitt, 2008),
sequential Monte Carlo (SMC) methods (Moral et al., 2006) and the integrated
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nested Laplace approximation (INLA) framework (Rue et al., 2009). In this thesis,
we focused on the marginal likelihood p(D | S = s) estimation methods based on
a Laplace approximation.
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5.1 Abstract
The impact of censored survival data on Bayesian inference is assessed when es-
timating Bayesian Weibull mixture models through a simulation study and an ap-
plication to microarray data. The simulation study was carried out with different
parameter configurations of the mixture model, that is, two well-separated com-
ponents and two strongly overlapping components for data generation each with
five different levels of censoring. The Bayesian approach via Markov Chain Monte
Carlo was used to estimate the parameters of Weibull mixture model. The issue of
label switching and model evaluation are also considered.
5.2 Introduction
In many cases, the application of a single parametric distribution is not sufficient
to describe the complexity of the data being observed. For instance, the data may
have been generated from several (possible uncensored) homogenous subgroups. To
produce a better inference, these groups should be taken into consideration. They
may also be needed to make appropriate inferential methodology considers such
subgroups for estimation and prediction.
Mixture models are usually used in modelling data consisting of several groups,
where each group has different properties and characteristics of the one family but
use the same distribution. This model provides a convenient and flexible mechanism
for identification and estimation of distributions which are not well modelled by
any standard parametric family (Stephens, 1997). This is achieved by assuming
that the observed data can be represented by a weighted sum of distributions, with
each distribution defined by a unique parameter set representing a subspace of the
population.
Weibull mixture models have received increasing attention in recent statistical
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research with applications in the field of survival and reliability analysis. The
advances in EM algorithm (Dempster et al., 1977), the Bayesian paradigm (Berger,
1985, Besag et al., 1995), and Markov chain Monte Carlo (MCMC) computational
methods (Diebolt and Robert, 1994) have substantially expanded the methodology
and application of Weibull mixture models. For example, in the Bayesian context,
Marin et al. (2005a) described methods to fit a Weibull mixture model with an
unknown number of components. Farcomeni and Nardi (2010) proposed a two
component mixture to describe survival times after an invasive treatment. Qian
(1994) also used a mixture of a Weibull component and a surviving fraction in the
context of a lung cancer clinical trial. Tsionas (2002) considered a finite mixture of
Weibull distributions with a larger number of components for capturing the form of
a particular survival function.
One important issue in the use of Weibull mixture models is the impact of
censored data. Censoring is an inherent feature of survival and reliability data,
and arises when part of the lifetime distribution is unobserved (usually at the end of
the study) for a variety of reasons, such as some individuals are still alive at the end
of the study or analysis of the event of interest, namely death, has not occurred.
There is growing literature for fitting mixture models to censored data. For ex-
ample, Miyata (2011) used the maximum likelihood estimator for fitting a mixture
of Exponential distributions and a mixture of Normal distributions with censored
data, and Hanson (2006) modelled censored lifetime data using a mixture of gam-
mas. An overview can be found in Ibrahim et al. (2001b).
The main aim of this paper is to investigate the impact of censoring on a finite
mixture of Weibull distributions either with or without covariates. This aim is
addressed through the estimation of a two component Weibull mixture model in
a simulation study and an application to a microarray dataset. The number of
components need not be confined to two. Farcomeni and Nardi (2010) stated that
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while extending the model to the general case is straightforward, in their experience
the two Weibull mixture is already sufficiently flexible. The simulation study inves-
tigates the aim by varying the censoring proportion when generating data. This is
evaluated for two model structures: two components that are quite different and two
components that are overlapping. The application to a microarray dataset relates to
Diffuse Large B-Cell Lymphoma (DLBCL) patients is described in further detail in
Section 5.4.2.
The paper is organised as follows. In Section 5.3, we define the Weibull mixture
model and Bayesian computational approach for parameter estimation. We also
provide the formal definition of censoring, describe the method of simulation and
discuss the issue of label-switching and model evaluation. In Section 5.4, we
illustrate the model using simulated datasets and a microarray dataset. The results
are discussed further in Section 5.5.
5.3 Methods
5.3.1 Model formulation
In this section, we define the Weibull mixture model for analysing survival data. We
confine ourselves to survival times that are the difference between a nominated start
time and a declared failure (uncensored data) or a nominated end time (censored
time). Let T be a nonnegative random variable for a person’s survival time and t be
any specific value of interest as a realisation of the random variable T . Kleinbaum
and Klein (2005) give some reasons for the occurrence of right censoring in survival
studies, including termination of the study, drop outs, or loss to follow-up. For
the censored observations, one could impute the missing survival times or assume
that they are event-free. The former is often difficult, especially if the censoring
proportion is large, and extreme imputation assumptions (such as all censored cases
fail right after the time of censoring) may distort inferences (Leung and Elashoff,
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1997, Stajduhar et al., 2009). In this study, we treat all censored cases as event-free
regardless of observation time.
Initially, we assume that we observe survival time t on patients possibly from a
heterogeneous population. The two parameter Weibull density function for survival
time is given by
W (t | α, γ) = αγtα−1 exp (−γtα) ,
for α > 0 and γ > 0, where α is a shape parameter and γ is a scale parameter
(Ibrahim et al., 2001b). A mixture of K Weibull densities(Marin et al., 2005a) is
defined by
f(t | K,pi,α,γ) =
K∑
m=1
pimW (t | αm, γm), (5.1)
where α = (α1, . . . , αK), γ = (γ1, . . . , γK), are the parameters of each Weibull
distribution and pi = (pi1, . . . , piK) is a vector of nonnegative weights that sum to
one.
The corresponding survival function S(t | K,pi,α,γ) and hazard function h(t |
K,pi,α,γ) are as follows:
S(t | K,pi,α,γ) =
K∑
m=1
pim exp (−γmtαm) ,
h(t | K,pi,α,γ) = f(t | K,pi,α,γ)/S(t | K,pi,α,γ).
Let xij be the jth covariate associated with patient i, for j = 1, 2, . . . , p. In our
application, xij could indicate, for example, the gene expressions. The covariates
can be included in the model as follows (Farcomeni and Nardi, 2010)
log(γm) = x
′
iβm = λm, (5.2)
where xi = (xi1, . . . , xip), γm = (γ1m, . . . , γpm) and βm = (β1m, . . . , βpm), for
i = 1, 2, . . . , n and m = 1, 2, . . . , K.
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We now assume that we observe possibly right-censored data for n patients;
y = (y1, . . . , yn) where yi = (ti, δi) and δi is an indicator function such that (Marin
et al., 2005a):
δi =
1, if the lifetime is uncensored, i.e., Ti = ti.0, if the lifetime is censored, i.e., Ti > ti.
Thus, the likelihood function becomes:
L (pi,α,γ | K, ti, δi,x) ∝
n∏
i=1
f (ti | K,pi,α,γ,x)δi S (ti | K,pi,α,γ,x)1−δi
Here, the incomplete information is modelled via the survivor function, which
reflects the probability that the ith patient was alive for duration greater than ti.
In WinBUGS (Lunn et al., 2000, Ntzoufras, 2009, Spiegelhalter et al., 2002),
possibly right censored data can be modelled using a missing data approach via the
command I(., ) as follows
t[i] ∼ dweib(alpha[i], gamma[i])I(cens.time[i], )
where cens.time[i] is either zero for uncensored outcome or the ith recorded sur-
vival time for censored outcomes. Hence, censored survival times are assumed to
be drawn from a truncated Weibull distribution.
The following prior distributions were placed on the parameters pi and α:
pi | K ∼ Dirichlet(φ1, . . . , φK), φm = φ,∀m = 1, 2, . . . , K.
αm ∼ Gamma(uα, vα),m = 1, 2, . . . , K.
For a model without covariates, we employ the following prior for γm.
γm ∼ Gamma(uγ, vγ),m = 1, 2, . . . , K.
We choose small positive values for uα, vα, uγ, vγ to express vague prior knowledge
about these parameters and we set φ = 1 (Marin et al., 2005a). For a model with
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covariates, in this thesis, we employed an independent normal prior on each βm, so
that
βm | K ∼ N(0,Σ),
and we allow Σ to be diagonal with elements σ2j , j = 1, 2, . . . , p. Again, we express
a vaguely informative prior by setting σ2j = 10. The diagonal matrices were used
here but this changed recently (Bhadra and Mallick., 2013), so one may argue that
a non-diagonal variance-covariance matrix may be more appropriate. However,
since the point of this simulation study was to assess the impact of censoring, so a
diagonal variance matrix should suffice for this purpose.
Alternatively, we could have employed a multivariate normal prior on βm, so
that
βm | K ∼MVN(µ,Σ),
where the population precision matrix Σ was assumed to follow a Wishart (R, ρ)
distribution. To represent vague prior knowledge, we can choose the the degrees
of freedom ρ for this distribution to be as small as possible and specify the scale
matrix R. This prior allows covariance terms to be estimated/ non-zero.
5.3.2 Computational Method
The model described in Section 5.3.1 can be fitted using MCMC sampling with
latent values Zi to indicate component membership of the ith observation (Diebolt
and Robert, 1994, Robert and Casella, 2000). Since pim = Pr(Zi = m), we can
write Zi ∼ M(pi1, . . . , piK). In this scheme, the Zi are sampled by computing
posterior probabilities of membership, and the other parameters are sampled from
their full posterior distributions, conditional on the latent indicators. This was
implemented in the WinBUGS software package (Lunn et al., 2000).
Label switching, caused by non-identifiability of the mixture components, was
dealt with post-MCMC using the reordering algorithm of Marin et al. (2005b). The
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algorithm proceeded by selecting the permutation of components at each iteration
that minimised the vector dot product with the so-called “pivot”, a high density point
from the posterior distribution. The MCMC output was then reordered according
to each selected permutation. In this paper, the approximate maximum a posteriori
(MAP) (i.e. The realization of parameters corresponding to the MCMC iterate that
maximised the unnormalised posterior) was chosen as the pivot.
5.3.3 Model Evaluation
The appropriateness of the Weibull model can be assessed by applying goodness
of fit measures which summarise the discrepancy between observed values and the
values expected under the model in question (Gupta et al., 2008).
The most commonly used assessment of model fit is a comparison between the
posterior predictive distribution and the observed data, generally termed a posterior
predictive check (Gelman, 2003, Gelman et al., 2004). If a model fits the data
well, the observed data should be relatively likely under the posterior predictive
distribution.
A second form of model evaluation which can be useful in simulation studies
is calculating the root mean squared error (RMSE) for each parameter. The RMSE
is an indicator of the fit between the estimated and the true parameter values. A
smaller RMSE reflects a better model fit (Kenney and Keeping, 1962, Wackerly
et al., 2002). The Root Mean Squared Error (RMSE) is the square root of the
average squared distance of a data point from the fitted line. The RMSE was used
to assess the appropriateness of the Weibull model in investigating the impact of
censoring on fitting two-component Weibull mixture models. It extends straightfor-
wardly to parametric multivariate cases.
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5.3.4 Simulation study
The simulation study comprised of two sub-studies. The first addressed the issue of
censoring for a Weibull mixture model without covariates and the second incorpo-
rated covariate information.
For these studies, data were simulated from two component Weibull mixture
models with the following parameter configurations:
M1. Well-separated components, equal weights:
f(t | K,pi,α,γ) = 0.5W (3, 1) + 0.5W (2, 2).
M2. Strongly overlapping components, equal weights:
f(t | K,pi,α,γ) = 0.5W (2, 2) + 0.5W (2, 1.75).
Five censoring levels, C (0%, 10%, 20%, 50%, 80%), were applied to each
model and a sample size of n = 200 was used for all experiments.
Sub-study 1. We simulated a two component Weibull mixture model without
covariates. For each model (M1 and M2) and each censoring proportion (C), the
simulation algorithm is described as follows:
1. Generate ti, from the respective model, for i = 1, . . . , n.
2. Generate censoring times by assuming that the largest C% survival times are
right censored.
3. Fit the model based on the data yi = (ti, δi), with 100,000 iterations, discard-
ing the first 10,000 iterations as burn-in.
4. Record posterior estimates of the model parameters, namely median and stan-
dard deviation.
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5. Repeat step 1-4 100 times.
Sub-study 2. In this study, we simulated data from a two component Weibull
model with covariates. For each model (M1 and M2), the simulation algorithm
for this study follows from before with additional steps to generate each covariate
xi = (x1i, . . . , x5i) from independent standard normal distributions, then set γm
using equation 5.2. For the purpose of the simulation study, we fixed the coefficient
values relating to the covariates in each component to β1 = (1, 1, 1, 1, 1) and β2 =
(2, 2, 2, 2, 2).
5.4 Results
5.4.1 Simulations
Sub-study 1. The median of posterior means and standard deviations of the Weibull
mixture parameters, based on the 100 simulations, for the two models with the
different censoring levels, are presented in Figures 5.1 and 5.2. Overall, the median
of posterior means of all parameter estimates slightly increases as the proportion of
censoring increases up to 50%. It is apparent that while the estimates are still rea-
sonably accurate for up to 50% censoring, the degree of accuracy slightly decreases
as the proportion of censoring increases. The RMSE values generally increase with
greater levels of censoring (Table 5.1).
A graphical comparison of the true models and the fitted models for C=0% are
given in Figure 5.3. The figure confirms the accuracy of the parameter estimates in
the absence of censoring. Figures 5.4 and 5.5 present corresponding graphs under
the censoring rates of 10%, 20%, 50%, and 80% confirming that increasing cen-
soring has a detrimental impact on estimation for a model both with well-separated
components (M1) and with strongly overlapping components (M2).
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Figure 5.1: Box-plots of posterior estimates of parameters (α,γ,pi) for model M1
with five different levels of censoring.
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Figure 5.2: Box-plots of posterior estimates of parameters (α,γ,pi) for model M2
with five different levels of censoring.
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Figure 5.3: Comparison of true and estimates densities for model M1 (top) and M2
(bottom).
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Table 5.1: Posterior estimates of parameters (α,γ,pi) and RMSE for model M1
and M2 with five different levels of censoring.
C Parameter
True value Posterior Mean RMSE
k = 1 k = 2 k = 1 k = 2 k = 1 k = 2
Model M1
0% α 3 2 2.9847 1.991 0.021 0.010
γ 1 2 1.005 2.007 0.003 0.010
pi 0.5 0.5 0.486 0.514 0.019 0.019
10% α 3 2 3.008 2.006 0.037 0.032
γ 1 2 1.014 2.014 0.005 0.012
pi 0.5 0.5 0.482 0.518 0.029 0.029
20% α 3 2 3.024 2.018 0.039 0.034
γ 1 2 1.017 2.022 0.006 0.019
pi 0.5 0.5 0.503 0.497 0.031 0.031
50% α 3 2 3.028 2.024 0.041 0.035
γ 1 2 1.023 2.027 0.009 0.025
pi 0.5 0.5 0.532 0.468 0.036 0.036
80% α 3 2 4.768 2.905 1.408 0.444
γ 1 2 1.729 1.047 0.543 0.456
pi 0.5 0.5 0.651 0.349 0.119 0.120
Model M2
0% α 2 2 2.009 2.017 0.026 0.019
γ 2 1.75 1.994 1.755 0.024 0.029
pi 0.5 0.5 0.497 0.503 0.038 0.038
10% α 2 2 2.016 2.003 0.038 0.022
γ 2 1.75 1.984 1.745 0.030 0.030
pi 0.5 0.5 0.474 0.526 0.040 0.040
20% α 2 2 2.031 1.986 0.040 0.026
γ 2 1.75 1.982 1.739 0.035 0.033
pi 0.5 0.5 0.492 0.508 0.042 0.042
50% α 2 2 2.151 2.141 0.051 0.033
γ 2 1.75 1.961 1.784 0.049 0.042
pi 0.5 0.5 0.532 0.468 0.049 0.049
80% α 2 2 4.65 2.392 3.605 0.166
γ 2 1.75 1.679 0.932 0.068 0.396
pi 0.5 0.5 0.249 0.751 0.258 0.257
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Figure 5.4: Comparison of true and estimated densities for model M1 (well-
separated components) with (a) 10%, (b) 20%, (c) 50%, and (d) 80% censoring.
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Figure 5.5: Comparison of true and estimated densities for model M2 (two
overlapping components) with (a) 10%, (b) 20%, (c) 50%, and (d) 80% censoring.
Sub-study 2. The results of this study are presented in Figures 5.6 and 5.7.
Overall, the median of the posterior means of shape parameter (α) over all simula-
tions was slightly higher than the true value as the level of censoring increases up to
50%. For both models (M1 and M2), the RMSE values of βm from 0% censoring to
intermediate-censoring (50%) for M1 and M2 are relatively the same. However, in
the case of heavy-censoring (80%), the RMSE of α for M2 is substantially higher
than M1 (Tables 5.2 and 5.3).
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Figure 5.6: Box-plots of posterior estimates of parameters (α,βm,pi) for model
M1 with five different levels of censoring.
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Figure 5.7: Box-plots of posterior estimates of parameters (α,βm,pi) for model
M2 with five different levels of censoring.
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Table 5.2: Posterior estimates of parameters (α,pi,βm) and RMSE for model M1
with five different levels of censoring.
C Parameter
True value Posterior Mean RMSE
k = 1 k = 2 k = 1 k = 2 k = 1 k = 2
0% α 3 2 3.009 1.998 0.016 0.019
β1 1 2 0.998 1.991 0.002 0.002
β2 1 2 0.998 1.996 0.001 0.002
β3 1 2 1.004 2.002 0.002 0.004
β4 1 2 1.005 2.005 0.002 0.004
β5 1 2 0.996 1.998 0.001 0.004
pi 0.5 0.5 0.496 0.505 0.003 0.003
10% α 3 2 2.984 1.995 0.020 0.023
β1 1 2 1.004 2.018 0.002 0.003
β2 1 2 1.010 1.993 0.002 0.001
β3 1 2 0.993 2.003 0.003 0.003
β4 1 2 0.991 1.992 0.002 0.001
β5 1 2 0.993 1.995 0.002 0.002
pi 0.5 0.5 0.503 0.497 0.001 0.001
20% α 3 2 2.982 2.019 0.021 0.027
β1 1 2 1.006 1.998 0.004 0.002
β2 1 2 1.012 1.993 0.003 0.004
β3 1 2 1.003 1.995 0.003 0.001
β4 1 2 1.013 2.017 0.002 0.001
β5 1 2 1.006 1.997 0.002 0.002
pi 0.5 0.5 0.500 0.500 0.001 0.001
50% α 3 2 3.051 1.994 0.031 0.033
β1 1 2 0.995 2.025 0.001 0.003
β2 1 2 0.986 1.991 0.004 0.002
β3 1 2 1.007 2.015 0.001 0.003
β4 1 2 1.016 1.983 0.002 0.004
β5 1 2 0.992 1.998 0.002 0.003
pi 0.5 0.5 0.509 0.491 0.001 0.001
80% α 3 2 2.783 1.912 0.046 0.043
β1 1 2 1.034 2.073 0.013 0.014
β2 1 2 0.975 2.017 0.024 0.029
β3 1 2 1.015 1.992 0.015 0.012
β4 1 2 0.979 1.973 0.027 0.014
β5 1 2 0.985 1.971 0.064 0.017
pi 0.5 0.5 0.508 0.493 0.003 0.003
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For the posterior variances, the median and the variance based on 100 simu-
lations also slightly increases in the presence of intermediate censoring for both
models. However, the median and the variability for M2 is substantially higher
compared to M1 with heavy censoring.
Overall, the posterior estimates of parameters for M1 are better, with respect to
accuracy and precision than M2 in the presence of increasing levels of censoring.
5.4.2 Application Using Real Data
Here, we analyse a dataset published by Rosenwald et al. (2002) to illustrate the
impact of censoring on the presented method for fitting the Weibull mixture model
from data. This dataset contains gene expression data from Diffuse Large B-cell
Lymphoma (DLBCL) patients, comprising 124 uncensored patients (56.6%) and 95
censored patients (43.4%). Patients with missing values for a particular microarray
element were excluded from all analyses involving that element.
Based on patterns of gene expression in biopsy specimens of the lymphoma,
Rosenwald et al. (2002) analysed this dataset to predict the likelihood of patients’
survival after chemotherapy for DLBCL. By using a Cox PH model, Rosenwald
et al. (2002) identified five individual gene expressions which correlated with the
survival after chemotherapy. These gene expressions are germinal center B-cell
(GC-B), lymphoma node, proliferation, BMP6 and MHC.
We used the DLBCL data in two ways. First, we analysed the original dataset
using the model and method described in Section 5.3. Second, we investigated
the impact of censoring on real data by taking the uncensored observation and
artificially inducing different censoring rates.
We fitted Weibull mixture models to the original dataset using the prior distri-
butions described in Section 5.3. The model with covariates described in Section
5.3 was fitted by using the individual gene expressions mentioned earlier as the
98 CHAPTER 5. IMPACT OF CENSORED SURVIVAL DATA
covariates, with survival times as the dependent variable. As in the simulation
study, we ran the MCMC algorithm with 100,000 iterations, discarding 10,000 as
burn-in. Summary statistics of the posterior distributions of the models are given
in Table 5.4. We can see that the only lymphoma signature substantially described
patients’ survival times and had a negative effect on the expected survival time in the
first component. In the second component, GC-B signature, lymphoma signature,
proliferation signature, BMP6 signature and MHC signature substantially described
patients’ survival times and GC-B signature and MHC signature had a negative
effect on the predicted survival time.
To investigate the impact of censoring, we selected all 124 uncensored obser-
vations and set these as the new training dataset to estimate the model. We fitted
the Weibull mixture models to this new training dataset using the prior distributions
described in Section 5.3. As in the simulation study, we ran the MCMC algorithm
with 100,000 iterations, discarding 10,000 as burn-in.
To make censoring levels of 10%, 20%, 50% and 80%, we ordered all 124
training data from smallest to largest, found the relevant percentile for the censoring
time and set the top 10%, 20%, 50% and 80%, respectively, as censored). Then, we
fit new dataset to estimate the model and ran posterior predictive checks to explore
the uncertainty about the predictions.
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Table 5.3: Posterior estimates of parameters (α,pi,βm) and RMSE for model M2
with five different levels of censoring.
C Parameter
True value Posterior Mean RMSE
k = 1 k = 2 k = 1 k = 2 k = 1 k = 2
0% α 2 2 1.997 1.998 0.018 0.020
β1 1 2 0.992 2.004 0.004 0.003
β2 1 2 1.003 1.998 0.002 0.002
β3 1 2 1.003 1.999 0.003 0.004
β4 1 2 1.012 2.003 0.007 0.002
β5 1 2 0.997 1.990 0.003 0.004
pi 0.5 0.5 0.497 0.503 0.003 0.003
10% α 2 2 1.966 2.019 0.025 0.026
β1 1 2 1.013 1.990 0.007 0.017
β2 1 2 0.995 1.997 0.008 0.002
β3 1 2 1.008 1.991 0.003 0.003
β4 1 2 1.019 1.996 0.011 0.002
β5 1 2 1.013 1.985 0.009 0.004
pi 0.5 0.5 0.501 0.499 0.004 0.004
20% α 2 2 2.022 2.020 0.029 0.031
β1 1 2 1.004 1.992 0.012 0.024
β2 1 2 0.996 1.998 0.004 0.002
β3 1 2 0.991 2.033 0.005 0.003
β4 1 2 1.016 1.989 0.003 0.003
β5 1 2 0.987 1.974 0.007 0.002
pi 0.5 0.5 0.508 0.492 0.004 0.004
50% α 2 2 2.068 2.025 0.039 0.037
β1 1 2 1.017 1.987 0.013 0.030
β2 1 2 0.998 2.008 0.009 0.004
β3 1 2 0.946 2.049 0.009 0.012
β4 1 2 0.980 1.971 0.011 0.005
β5 1 2 1.026 1.972 0.013 0.003
pi 0.5 0.5 0.496 0.504 0.005 0.005
80% α 2 2 2.483 2.457 0.123 0.125
β1 1 2 1.073 2.021 0.027 0.033
β2 1 2 0.843 1.952 0.035 0.005
β3 1 2 0.940 1.963 0.036 0.007
β4 1 2 0.980 1.965 0.043 0.005
β5 1 2 0.984 1.953 0.028 0.012
pi 0.5 0.5 0.480 0.520 0.003 0.003
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Tables 5.5 and 5.6 display the posterior predictive distributions for DLBCL
dataset for five levels of censoring. The uncertainty in the credible interval (CI)
of posterior predictive check increases as the level of censoring increases. From
Table 5.6, only the lymphoma signature substantially described patients’ survival
times in the first component, with a negative effect on the predicted survival time.
In the second component, lymphoma signature, proliferation signature and MHC
signature substantially described patients’ survival times and lymphoma signature
and MHC signature had a negative effect on the predicted survival time.
Table 5.4: Posterior summary statistics for DLBCL data.
Model Parameters Median Sta.Dev 95% CI
Without covariates α1 0.883 0.270 (0.6810, 1.0480)
α2 1.304 0.271 (1.1610, 1.4380)
γ1 0.108 0.166 (0.0315, 0.0977)
γ2 0.794 0.323 (0.0673, 0.9483)
w1 0.611 0.071 (0.5570, 0.6561)
w2 0.389 0.071 (0.3439, 0.4430)
With covariates α1 0.855 0.259 (0.384, 1.384)
α2 0.548 0.056 (0.441, 0.659)
GC-B β11 0.153 0.093 (-0.029, 0.337)
β12 -2.863 0.462 (-3.776,-1.972)
Lymphoma β21 -0.629 0.102 (-0.829, -0.429)
β22 3.238 0.661 (2.023, 4.585)
Proliferation β31 0.013 0.148 (-0.281, 0.303)
β32 2.608 0.611 (1.408, 3.812)
BMP6 β41 0.051 0.120 (-0.189, 0.282)
β42 2.142 0.493 (1.194, 3.14)
MHC β51 0.116 0.097 (-0.069, 0.312)
β52 -5.358 0.676 (-6.7, -4.065)
w1 0.68 0.048 (0.582, 0.773)
w1 0.32 0.048 (0.227, 0.417)
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Table 5.5: Summary of posterior predictive checks for predicted survival times with
five different levels of censoring.
Obs t
95% CI for predicted survival times
C=0% C=10% C=20% C=50% C=80%
1 9.1 (1.8089,6.88) (1.72,7.46) (1.77,8.45) (1.36,8.878) (1.405,21.05)
2 5.6 (0.6138,5.684) (0.3289,15.56) (0.4641,27.830) (0.598,29.50) (0.66,30.13)
3 4.3 (0.1241,1.025) (0.3795,2.892) (0.6294,14.26) (1.61,10.21) (2.002,29.86)
4 2.3 (0.3605,2.363) (0.3078,2.538) (0.4433,2.614) (2.50,6.10) (2.70,7.28)
5 1.5 (0.3208,1.905) (0.307,2.382) (0.4554,2.723) (0.24,2.63) (0.08,1.21)
6 10.6 (0.3116,2.152) (0.1243,13.3) (0.0205,17.07) (31.17,55.68) (20.44,53.16)
7 6.2 (0.3646,3.014) (0.110,4.880) (0.2491,4.512) (0.99,6.28) (1.56,22.13)
8 1.9 (0.4292,2.196) (0.2954,2.391) (0.319,2.381) (0.58,2.41) (0.06,1.446)
9 1.2 (0.1071,1.221) (0.1145,1.215) (0.2607,1.549) (0.63,3.98) (1.24,17.31)
10 1 (0.593,1.008) (0.1265,1.019) (0.263,1.567) (0.34,2.16) (0.46,6.579)
11 0.7 (0.2529,1.163) (0.1484,1.234) (0.1829,1.5) (0.26,1.64) (0.12,2.006)
...
...
...
...
...
...
...
124 0.1 (0.09,1.017) (0.0983,1.1023) (0.0897,0.111) (0.05,0.24) (0.0649,0.159)
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Table 5.6: Summary of posterior predictive checks for parameters with five
different levels of censoring.
Parameter
95% CI for parameters
C=0% C=10% C=20% C=50% C=80%
α1 (0.7794,0.9608) (0.8207,1.03) (0.766,1.018) (0.7405,1.05) (0.422,0.8158)
α2 (1.125,1.247) (0.94,1.311) (0.8959,2.462) (1.229,3.201) (1.044,3.304)
β11 (-0.127,0.133) (-0.373,0.413) (-0.323,0.473) (-0.65,0.964) (-0.603,1.121)
β12 (-0.045,0.125) (-0.026,0.155) (0.157,0.384) (0.205,0.456) (0.205,0.656)
β21 (-0.289,-0.048) (-0.416,-0.138) (-0.389,-0.045) (-0.459,-0.038) (-0.562,-0.008)
β22 (-0.207,-0.012) (-0.225,-0.001) (-0.362,-0.095) (-0.43,-0.12) (-0.73,-0.32)
β31 (-0.112,0.189) (-0.133,0.166) (-0.162,0.169) (-0.132,0.219) (-0.122,0.402)
β32 (0.166,0.321) (0.025,0.221) (0.124,0.393) (0.174,0.458) (0.132,0.645)
β41 (-0.078,0.134) (-0.052,0.161) (-0.087,0.137) (-0.058,0.234) (-0.178,0.157)
β42 (-0.073,0.046) (-0.081,0.044) (-0.051,0.089) (-0.122,0.146) (-0.057,0.351)
β51 (-0.264,0.086) (-0.07,0.296) (-0.086,0.289) (-0.1,0.355) (-0.21,0.674)
β52 (-0.281,-0.066) (-0.267,-0.046) (-0.272,-0.057) (-0.381,-0.046) (-0.263,-0.022)
λ1 (2.861,13.87) (2.867,13.89) (2.878,13.94) (2.891,13.89) (2.849,13.84)
λ2 (2.871,13.86) (2.872,13.89) (2.873,13.86) (2.873,13.86) (2.845,13.82)
w1 (0.846,0.894) (0.849,0.9) (0.822,0.869) (0.751,0.805) (0.575,0.638)
w2 (0.105,0.155) (0.1,0.151) (0.131,0.178) (0.195,0.249) (0.361,0.425)
5.5 Discussion
This study has examined the impact of censoring on fitting two-component Weibull
mixture models either with or without covariates. Overall, the results of the simula-
tions show that censoring has an effect on the performance of the Weibull mixture
models in that, as the proportion of censoring increases, poorer parameter estimates
were obtained in terms of both bias and precision. Our study also supports the work
of Lagakos (1979) who indicated that when the amount of censoring is small, very
little bias is likely to result. More specifically, the results of our study confirmed
those of Stajduhar et al. (2009) who showed that an acceptable model of survival
data can still be obtained with light censoring up to 20%. However, the latter
study indicated that under the same circumstances with 50% or 80% censoring,
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bias is likely to result. In contrast, our study showed that for both models with and
without covariates censoring up to 50% resulted in relatively unbiased estimation
and only heavier censoring up to 80% resulted in a break-down of the mixture
estimation. For the model without covariates, this break-down was indicated by
biased parameter estimates based on both posterior means and posterior variances.
The inaccuracy of the parameter estimates is evident in a comparison of true and
estimated densities for the models, and larger RMSE values of the models. For
the model with covariates, the biased estimates of shape parameter obtained either
for the posterior means or the posterior variances and larger RMSE values of the
models indicated the break-down.
Censoring had a different effect on the mixture, depending on the “closeness”
of the components. It had greater impact on parameter estimation for strongly
overlapping components (M2) especially for the shape parameter (α), compared
to analogous estimation of well separated components (M1). These findings are
in line with the study of Grodzenskii and Domrachev (2002) who concluded that
the quality of estimates of parameters of a mixture model decreases in the presence
of increasingly larger levels of censoring. For the simulation study, Type II right
censoring (Kalbfleisch and Prentice, 2002, Lawless, 2002), was used to generate
the data. There exist, however, different censoring mechanisms also encountered in
practice that could have been explored, for example, random censoring (Liu, 2012,
Miller, 1998). While not considered in the present study, the impact of different
censoring mechanisms on mixture model estimation represents an opportunity for
future research.
Label switching is a known problem in mixture model analysis. The problem
arises from the invariance of the likelihood with respect to the permutations of the
component labels in the mixture model (Marin et al., 2005b, Mengersen et al.,
2011, Stephens, 2000a). As a result, the marginal distributions of the parameters
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are identical for all components and the posterior expectations for the parameters
are also identical. The approach used in this paper to correct label switching in
the MCMC output worked well. However, there exist a number of alternative
approaches in the literature that could also have been used. Green (1995) proposed
a new framework for the construction of reversible Markov chain samplers that
jump between parameter subspaces of differing dimensionality, which is flexible
and entirely constructive. Following this, Stephens (2000a) proposed an alternative
of reversible jump methods for dealing with Bayesian analysis of mixture models
with unknown number of components. Stephens (2000b) and Celeux et al. (2000)
also describe an alternative approach, called relabelling algorithms, that involve
the minimisation of the posterior expected loss under a class of loss functions.
Fruhwirth-Schnatter (2000) proposed “permutation MCMC”, as means of choosing
prior constraints to reduce the occurrence of label switching. A detailed review of
these approaches and others features in Jasra et al. (2005). More recently, Roodaki
et al. (2013) addressed the problems of relabeling and summarising posterior distri-
butions that typically arise when dealing with signal decomposition problems with
an unknown number of components.
Apart from bias and precision criteria used for investigating the impact of cen-
soring in the finite mixture of Weibull distribution, the Bayesian approach cou-
pled with MCMC enable us to estimate the parameters of Weibull mixture survival
models for dealing with such censored data situations, maintain identifiability and
deal with the problem of label switching. These are a significant advantage of the
proposed Bayesian approach. Furthermore, the flexibility of Bayesian approach,
ease of extension to more complicated scenarios such us a cure mixture model,
relief of analytic calculation of likelihood function, particularly for non-tractable
likelihood functions and ease of coding with available packages should be consid-
ered as additional benefits of the proposed Bayesian approach to estimate survival
times.
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6.1 Abstract
This study considered the problem of predicting survival, based on three alterna-
tive models: a single Weibull, a mixture of Weibulls and a cure model. Instead
of choosing a “best” model, a Bayesian model averaging (BMA) approach was
adopted to account for model uncertainty. This was illustrated using a case study
in which the aim was description of lymphoma cancer survival with covariates
given by phenotypes and gene expressions. The results of this study indicate that
if the sample size is sufficiently large, model emerges as the best fit. In the case
study, only one model dominated, based on goodness of fit as indicated by the
Bayesian Information Criterion (BIC). However, the result was different when the
model selection process was applied to the phenotype subgroups of the patients.
In this case, there was no dominant model and a BMA approach was appropriate.
Although BMA can compromise on goodness of fit to the data used in the analysis,
it can provide more accurate and robust predictions and facilitates more detailed
investigation of the relationships between gene expression.
6.2 Introduction
Modelling survival data plays an important role in the application of statistics in
medicine and health science. In addition to nonparametric formulation, there are
many parametric models available for describing survival, including models based
on a single distribution such as the Exponential and Weibull, mixture models based
for example on mixtures of Weibulls and a mixture of susceptible and unsusceptible
individuals or so-called cure models which account for a fraction of the patients
being cured from the disease. Given the wealth of models, the dilemma that is
faced by many practitioners is the choice of a survival model.
The problem of model selection is abundant throughout the literature. This
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includes both covariate selection and choice of the model itself. Some of the meth-
ods are based on a series of significance tests while others fit more comprehensive
models; some include prior information; some use analytic or approximate methods
of estimation while others use Markov Chain Monte Carlo (MCMC) methods;
different approaches use different optimisation or model comparison criteria such
as Bayes factors (Raftery, 1996). For example, McGrory and Titterington (2007)
showed how variational techniques can be used to extend the deviance information
criterion (DIC) to include the comparison of mixture models, Basu and Tiwari
(2010) used Bayes factors to compare the various model structures in breast cancer
survival data.
Recently, Bonato et al. (2011) proposed Bayesian ensemble methods to obtain
better survival prediction in high-dimensional gene expression data. Regardless
of the method, the most common approach is to choose a single model based on
the adapted optimisation or model choice criterion. However, if a single model is
selected, then inferences are conditional on the selected model, and model uncer-
tainty is ignored which often leads to excessively narrow or misleading inferences
(Raftery et al., 1997), (Hjort and Claeskens, 2003). This difficulty can be overcome
by combining the information provided by all suitable models into the analysis. The
most common way of achieving this is to use a form of model averaging. From a
Bayesian point of view, this averaging is applied such that the posterior distribution
of the quantity of interest is obtained over the set of suitable models, weighted by
the respective posterior model probabilities (Raftery, 1996).
Draper (1995) and Raftery (1995) reviewed BMA and the cost of ignoring model
uncertainty. Madigan and Raftery (1994) also considered BMA by using Occam’s
razor and Occam’s window approaches to reduce the number of candidate mod-
els. Yuan and Yin (2011) used model averaging procedures to make more robust
inferences regarding the dose-finding design for phase I clinical trials. Pramana
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et al. (2012) focused on the case in which several parametric models are fitted to
gene expression data and discussed model averaging techniques for the estimation
of dose-response models.
In this paper, we consider the problem of predicting survival, based on three
alternatives models; a single Weibull, a mixture of Weibulls and a cure model.
Instead of choosing a “best” model, we adopt a Bayesian model averaging approach
to account for model uncertainty in the prediction of the response. We illustrate the
approach using a microarray dataset.
The paper is organised as follows. In Section 6.3, we define BMA. The three
competing models are described in a Bayesian framework in Section 6.4. The
computational approach for estimation is also presented in this section. In Section
6.5, we illustrate the model using a real dataset. The results are discussed further in
Section 6.6.
6.3 Methods
The key elements of BMA were discussed by Raftery (1995). He suggested weight-
ing each model by the posterior model probabilities derived from a Bayesian anal-
ysis. Assume that there are S models being considered, for s = 1, 2, . . . , S, each
with parameter set θs based on data D. Let ∆ be the quantity of interest; this
could represent, for example, the posterior predictive distribution of y. Hence, the
posterior distribution of ∆ given data D (Hoeting et al., 1999) is
p(∆ | D) =
S∑
s=1
p(∆ | S = s,D)p(S = s | D)
where p(S = s | D) is the posterior probability of a particular model being true,
defined as
p(S = s | D) = p(D | S = s)p(S = s)∑S
s=1 p(D | S = s)p(S = s)
, s = 1, 2, . . . , S,
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where p(D | S = s) = ∫ p(D | θs, S = s)p(θs | S = s)dθs
Here, p(D | S = s) is the marginal likelihood of the data D given model S and
p(θs | S = s) is the prior density of θs given model S = s. p(S = s) is the prior
probability for models being true (Hoeting et al., 1999).
Given a model selection problem in which we have to choose between two
models, the plausibility of the two different models S1 and S2 is assessed by the
Bayes factor as the ratio of posterior model probabilities.
The main detractor from using Bayes factors is that they are, in general, difficult
to compute. Raftery (1995) proposed using BIC (Schwarz, 1978b) as an approx-
imation. Buckland et al. (1997) and Claeskens and Hjort (2008) discussed the
utilization of BIC in Bayesian model averaging. Buckland et al. (1997) proposed
simpler methods where weights are based upon the penalized likelihood functions
formed from the AIC (Akaike, 1973).
The starting point for Burnham and Anderson’s model selection theory is the
Kullback-Leibler (KL) information given by Burnham and Anderson (2002) and
Claeskens and Hjort (2008):
I(f | q) =
∫
f(x) log
f(x)
q(x | θs)dx,
where f represents the density function of the true and unknown model, q represents
the density function of the model that is used to approximate f , and θs is a vector
of the unknown parameters to be estimated. The notation I(f | q) denotes the
information lost when q is used to approximate f or the distance from q to f . For
a given set of models, one can compare the KL information for each model and
select the model that minimizes the information loss across the considered set of
models (Burnham and Anderson, 2002), (Burnham and Anderson, 2004). How-
ever, in practice I(f | q) cannot be computed since the true model f is unknown.
Schwarz (1978b) and Burnham and Anderson (2002) made the link between the KL
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information and likelihood theory and showed that the expected KL information can
be expressed as
E(KL) = − log p(D | θˆs, S = s) + ds log(n),
where p(D | θs) is the likelihood, ds is the number of parameters in the model
and n is the number of uncensored observations in a survival context (Volinsky
and Raftery, 2000). A Laplace approximation, typically the Bayesian Information
Criterion (BIC, Schwarz (1978b)) can be used to approximate p(D | S = s) (Clyde,
2000, Hoeting et al., 1999, Jackson et al., 2009, Yuan and Yin, 2011):
log (p(D | S = s) ≈ log p(D | θˆs, S = s)− ds log(n)
BIC = −2 log p(D | θˆs, S = s) + ds log(n). (6.1)
Here log p(D | θˆs, S = s) is the maximised log-likelihood of model s, which
estimates goodness of fit of the data.
Schwarz (1978b) and Burnham and Anderson (2002) proposed the likelihood of
the model given the data, using θˆs defined by
p(D | θˆs, S = s) ∝ e0.5×BIC (6.2)
The BMA weight for the sth model (Jackson et al., 2009, Yuan and Yin, 2011)
is given by
p(S = s | D) = exp(−
1
2
BICs)p(S = s)∑S
s=1 exp(−12BICs)p(S = s)
,
The BMA weight can be interpreted as the weight of the evidence that model
s is the best model given a set of S models. For the case with non-informative
prior probabilities, we can let p(S = s) equal for all candidate models (1/S),
indicating no prior preference for any of the models (Jackson et al., 2009), (Pramana
et al., 2012). The model with the highest BMA weight will be considered as the
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best model. Therefore, p(S = s | D) is also an approximation to the posterior
probability of the model s being correct (Schwarz, 1978b). A smaller BIC values
indicates a better model fit, accounting for model parsimony.
Let f˜sj be the jth simulated observation from the sth model. Then, the mean of
survival from the BMA model (f¯MA), can be calculated as follows
f¯MA =
(
N∑
j=1
S∑
s=1
wsf˜sj
)
/N, (6.3)
where N is the number of simulated observation and ws = p(S = s | D) is the
BMA weight, defined previously.
6.4 Models
6.4.1 Weibull Model
In this section, we define the Weibull model for analysing survival of patients
in the context of human health. We confine ourselves to survival times that are
the difference between a nominated start time and a declared failure (uncensored
data) or a nominated end time (censored time). Let T be a non-negative random
variable for a person’s survival time and t be a realisation of the random variable
T . Kleinbaum and Klein (2005) give some reasons for the occurrence of right
censoring in survival studies, including termination of the study, drop outs, or loss
to follow-up. For the censored observations, one could impute the missing survival
times or assume that they are event-free. The former is often difficult, especially if
the censoring proportion is large, and extreme imputation assumptions (such as all
censored cases fail right after the time of censoring) may distort inferences (Leung
and Elashoff, 1997), (Stajduhar et al., 2009). In this study, we treat all censored
cases as event-free regardless of observation time.
Initially, we assume that we observe survival times t of patients possibly from a
heterogeneous population. The two parameter Weibull density function for survival
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time is given by
W (t | α, γ) = αγtα−1 exp (−γtα) ,
for α > 0 and γ > 0, where α is a shape parameter and γ is a scale parameter
(Ibrahim et al., 2001b).
Since the logarithm of the Weibull hazard is a linear function of the logarithm
of time, it is more convenient to write the model in terms of the parameterisation
λ = log(γ) (Ibrahim et al., 2001b), so that:
f(t | α, λ) = αtα−1 exp(λ− exp(λ)tα)
where t > 0, α > 0 and γ > 0.
The corresponding survival function and the hazard function, using the λ pa-
rameterization, are as follows:
S(t | α, λ) = exp(− exp(λ)tα),
h(t | α, λ) = f(t | α, λ)/S(t | α, λ) = α exp(λ)tα−1.
We now assume that we observe possibly right censored data for n patients;
y = (y1, . . . , yn) where yi = (ti, δi) and δi is an indicator function such that (Marin
et al., 2005a):
δi =
1, if the lifetime is uncensored, i.e., Ti = ti.0, if the lifetime is censored, i.e., Ti > ti.
Let xij be the jth covariate associated with ti for j = 1, 2, . . . , p + 1. In our
case study, xij indicates the p gene expressions from DNA microarray data, and xi0
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indicates the multi-category phenotype covariate. The data structure is as follows:
Survival time
t1
t2
...
tn


Category Gene 1 . . . Gene p
x10 x11 . . . x1p
x20 x21 . . . x2p
...
...
...
...
xn0 xn1 . . . xnp
 .
The gene expression data can be included into the model through λ (Thamrin
et al., 2013). Given that λ must be positive, one option is to include the covariates
as follows:
γi = exp(x
′
iβ), so that
λi = log(γi) = x
′
iβ. (6.4)
Thus, the log-likelihood function becomes:
logL(α,β | D) =
n∑
i=1
δi
(
log(α) + (α− 1) log(ti)
+ x′iβ
)− exp(x′iβ)tαi .
We assume that (α, λ) are independent a priori (Marin et al., 2005a), and assign
Gamma distributions. Thus, the priors are now given by:
α ∼ Gamma(uα, vα)
λi ∼ Normal(x′iβ, σ2)
β ∼ Normal(0,Σ),
and we allow Σ to be diagonal with elements σ2j , j = 1, 2, . . . , p.
Diffuse priors are represented by large positive values for σ2, and small positive
values for uα and vα.
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The joint posterior distribution of (α,β) is given by:
p(β, α | D) ∝ L(α,β | D)p(α)p(β)
∝ αα0+d−1 exp
{
n∑
i=1
(δix
′
iβ + δi (α− 1) log (ti)− tαi exp (x′iβ))
−b0α− 1
2
(β − µ0) Σ−10 (β − µ0)
}
.
MCMC analysis is performed by sampling from the conditional distributions of
the parameters. The conditional distribution of α does not have an explicit form and
as such can be sampled from approximately algorithms such as Metropolis-Hastings
or slice sampling (Gilks et al., 1996).
6.4.2 Weibull Mixture Model
We define the Weibull mixture model for analysing survival data. A mixture of K
Weibull densities (Marin et al., 2005a) is defined by
f(t | K,w,α,γ) =
K∑
m=1
wmW (t | αm, γm), (6.5)
where α = (α1, . . . , αK), γ = (γ1, . . . , γK), are the parameters of each Weibull
distribution and w = (w1, . . . , wK) is a vector of nonnegative weights which sum
to one.
The corresponding survival function S(t | K,w,α,γ) and hazard function h(t |
K,w,α,γ) are as follows:
S(t | K,w,α,γ) =
K∑
m=1
wm exp (−γmtαm) ,
h(t | K,w,α,γ) = f(t | K,w,α,γ)/S(t | K,w,α,γ).
We now assume that we observe possibly right censored data for n patients;
y = (y1, . . . , yn) where yi = (ti, δi) and δi is an indicator function as described in
Section 6.4.1.
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Let xij be the jth covariate associated with patient i, for j = 1, 2, . . . , p. In our
application, xij could indicate, for example, the gene expressions. The covariates
can be included in the model as follows (Farcomeni and Nardi, 2010)
log(γm) = x
′
iβm = λm, (6.6)
where xi = (xi1, . . . , xip), γm = (γ1m, . . . , γpm) and βm = (β1m, . . . , βpm), for
i = 1, 2, . . . , n and m = 1, 2, . . . , K.
Thus, the likelihood function becomes:
L (w,α,γ | K, ti, δi,x) ∝
n∏
i=1
[
f (ti | K,w,α,γ,x)δi S (ti | K,w,α,γ,x)1−δi
]
Here, the incomplete information is modelled via the survivor function, which
reflects the probability that the patient was alive for duration greater than ti.
The following prior distributions are placed on the parameters w and α:
w | K ∼ Dirichlet(φ1, . . . , φK), φm = φ, ∀m = 1, 2, . . . , K.
αm ∼ Gamma(uα, vα),m = 1, 2, . . . , K.
For a model without covariates, we employ the following prior for γm.
γm ∼ Gamma(uγ, vγ),m = 1, 2, . . . , K.
We chose small positive values for uα, vα, uγ, vγ to express vague prior knowl-
edge about these parameters and we set φ = 1 (Marin et al., 2005a). For a model
with covariates, we employed an independent normal prior on each βm, so that
βm | K ∼ N(0,Σ),
and we allow Σ to be diagonal with elements σ2j , j = 1, 2, . . . , p. Again, we express
a vaguely informative prior by setting a large positive value for σ2j . The diagonal
matrices were used here but this changed recently (Bhadra and Mallick., 2013),
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so one may argue that a non-diagonal variance-covariance matrix may be more
appropriate.
The model described in this section can be fitted using MCMC sampling with
latent values Zi to indicate component membership of the ith observation (Diebolt
and Robert, 1994, Robert and Casella, 2000). Since wm = Pr(Zi = m), we can
write Zi ∼M(w1, . . . , wK). In this scheme, the Zi are sampled by computing pos-
terior probabilities of membership, and the other parameters are sampled from their
full conditional distributions. This was implemented in the WinBUGS software
package (Spiegelhalter et al., 2002).
Label switching, caused by non-identifiability of the mixture components, was
dealt with post-MCMC using the reordering algorithm of Marin et al. (2005b). The
algorithm proceeded by selecting the permutation of components at each iteration
that minimised the vector dot product with the so-called “pivot”, a high density point
from the posterior distribution. The MCMC output was then reordered according
to each selected permutation. In this paper, the approximate maximum a posteriori
(MAP) (i.e. the realization of parameters corresponding to the MCMC iterate that
maximised the unnormalised posterior) was chosen as the pivot.
6.4.3 Cure Model
As in Section 6.4.1, we observe time to the event of interest for n independent
subjects, and we let (ti, δi) denote the observed time and the event indicator for the
i-th observation. Let S1(t) be the survivor function for the entire population, S∗(t)
be the survivor function for the non-cured group in the population, and pi be the cure
rate function. Then the standard cure rate model is given by:
S1(t) = pi + (1− pi)S∗(t). (6.7)
The commonly used parametric distributions include Exponential and Weibull for
S∗(t).
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As in Yakovlev and Tsodikov (1996), Chen et al. (1999) and Ibrahim et al.
(2001b), for an individual in a population, let N denote the number of latent vari-
ables. Assume that N has a Poisson distribution with mean θ. Let Zi, i = 1, . . . , N
denote the random time, where Zi are independently and identically distributed
(i.i.d.) with a common distribution function F (t) = 1 − S(t). Also, assume that
Zi are independent of N . The time to event can be defined by the random variable
Y = min(Zi, 0 ≤ i ≤ N), where P (Z0 = ∞) = 1. Hence, the survival function
for the population is given by
Spop(t) = P (N = 0) + P (Z1 > t, . . . , ZN > t,N ≥ 1)
= exp(−θ) +
∞∑
k=1
[S(t)]k
θk
k!
exp(−θ)
= exp(−θF (t)). (6.8)
A corresponding cure fraction in model (6.8) is limt→∞ Spop(t) = exp(−θ) > 0.
We also know from (6.8) that the cure fraction is given by Spop(∞) = P (N =
0) = exp(−θ). As θ → ∞, the cure fraction tends to 0, whereas as θ → 0, the
cure fraction tends to 1. Corresponding population density and hazard functions are
fpop(t) = − ddtSpop(t) = θf(t) exp(−θF (t)) and hpop(t) = θf(t), respectively.
The proportional hazards structure with the covariates is modelled through θ
(Chen et al., 1999, Ibrahim et al., 2001b). The population survival function (6.7)
can be written as
Spop(t) = exp(−θ) + [1− exp(−θ)]S∗(t),
where S∗(t) = exp(−θF (t))−exp(−θ)
1−exp(−θ) , and f
∗(t) = exp(−θF (t))
1−exp(−θ) θf(t).
Following Chen et al. (1999) and Ibrahim et al. (2001b), we construct the like-
lihood function. Suppose we have n subjects and we assume that N ′i s are i.i.d with
Poisson distributions with means θi, i = 1, . . . , n. Let Zi1, . . . , ZiN denote the times
for the Ni competing causes, which are unobserved, and which have a cumulative
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distribution function, F (.). In this section, we will specify a parametric form for
F (.), that is a Weibull distribution. Letψ = (α, λ)′ , where α is the shape parameter
and λ is the scale parameter. We incorporate covariates for the cure rate model
through the cure parameter θ and we have a different cure rate parameter, θi, for
each subject.
Let x′i = (xi1, . . . , xip) denote the p x 1 vector of covariates for the ith subject,
and let β = (β1, . . . , βp) denote the corresponding vector of regression coefficients.
We relate θ to the covariates by θi = exp(x
′
iβ). Let ti denote the survival time for
subject i, which is right censored, let Ci be the censoring time, and let δi be the
censoring indicator, assuming 1 if Ti is a failure time and 0 if it is right censored.
The observed data are D = (n, t, δ,X), where t = (t1, . . . , tn)
′ , δ = (δ1, . . . , δn)
′
and X = (x1, . . . , xn)
′ . The complete data are given by Dc = (n, t, δ,X,N ),
whereN = (N1, . . . , Nn)
′ . The complete-data likelihood function of the parameter
(ψ,β) can be written as
L(ψ,β | Dc) =
{
n∏
i=1
S(ti | ψ)Ni−δi(Nif(ti | ψ))δi
}
× exp
{
n∑
i=1
Ni log(θi)− log(Ni!)− nθi
}
. (6.9)
Again, we assume independent priors for β and ψ, where α ∼ Gamma(aα, bα),
λ ∼ N(µλ,Σλ) and β ∼ N(µβ,Σβ). We also assume p(α, λ) = p(α | δ0, τ0)p(λ),
p(α | δ0, τ0) ∝ αδ0−1 exp(−τ0α), and the hyperparameters (δ0, τ0) are specified
(Chen et al., 1999, Ibrahim et al., 2001b).
Combining these specifications with the likelihood function (6.9), the joint pos-
terior distribution of (α, λ,β) becomes
p(α, λ,β | D) ∝
n∏
i=1
(θif(ti | α, λ))δi exp(−θi(1− S(ti | α, λ)))
×p(α | δ0, τ0)p(α, λ)p(β). (6.10)
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The joint posterior density of (α, λ,β) in equation (6.10) is analytically in-
tractable because the integration of the joint posterior density is not easy to perform.
Hence, inferences are based on MCMC simulation methods. We use the Metropolis-
Hastings algorithms or slice sampling to simulate samples of α, λ and β. MCMC
computations were implemented using the WinBUGS system (Spiegelhalter et al.,
2002).
6.5 Application Using Real Data
6.5.1 DLBCL Dataset
We applied the proposed method of model averaging across the three candidate
survival models to a dataset containing gene expression of Diffuse Large B-cell
Lymphoma (DLBCL). The dataset comprises gene expression measurements and
survival times of patients with DLBCL (Rosenwald et al., 2002). DLBCL (Lenza
et al., 2008) is a type of cancer of the lymphatic system in adults which can be
cured by anthracycline-based chemotherapy in only 35 to 40 percent of patients
(Rosenwald et al., 2002). In general, types of this disease are very diverse and
their biological properties are largely unknown, meaning that this is a relatively
difficult cancer to cure and prevent. Rosenwald et al. (2002) proposed that there
are three phenotypes subgroups of patients of DLBCL: activated B-like DLBCL,
germinal centre (GC)-B like and type III DLBCL. The GC B-like DLBCL is less
dangerous than the others in the progression of the tumour; the activated B-like
DLBCL is more active than the others and the type III DLBCL is the most dangerous
in the progression of tumour (Alizadeh et al., 2000). These groups were defined
using microarray experiments and hierarchical clustering. The authors showed that
these phenotypes subgroups were differentiated from each other by distinct gene
expressions of hundreds of different genes and had different survival time patterns.
This dataset contains 219 patients with DLBCL, including 138 patient deaths during
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follow-up. Patients with missing values for a particular microarray element were
excluded from all analyses involving that element.
Based on patterns of gene expression in biopsy specimens of the lymphoma,
Rosenwald et al. (2002) analysed this dataset to predict the likelihood of patients’
survival after chemotherapy for DLBCL. By using a Cox proportional-hazards model,
Rosenwald et al. (2002) identified five individual gene expressions which correlated
with the survival after chemotherapy. These gene expressions are germinal center
B-cell (GC-B), lymphoma node, proliferation, BMP6 and MHC. In this study, these
five gene expressions are used as covariates for estimating survival times based on
the three competing models in Section 6.4.
6.5.2 Results
As discussed in Section 6.3, to account for model uncertainty, the model averaging
technique which combines estimates from different survival models was carried
out. This was accomplished through a weighted average of the survival considered
in the analysis. First, we calculated the Kaplan-Meier estimates of overall survival
according to the gene expression and the relation between the gene expression score
and the subgroups phenotype of DLBCL. We confirmed that these phenotypes had
different survival time patterns (Figure 6.1). Following this, we fitted the three
models either to all gene expression data and to the three phenotype subgroups. We
then applied the BMA approach described in Section 6.3. For each model, we ran
the corresponding MCMC algorithm for 100 000 iterations, discarding the first 10
000 iterations as burn-in.
The model averaged prediction for the response was calculated according to
equation (6.3). Table 6.1 shows the estimated posterior mean of the parameters,
the 95% credible intervals (CI), the BIC values and the BMA weights for each
of the fitted models for the whole dataset. The BMA weights reflect the relative
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posterior probability of the models. As can be seen from Table 6.1, for the Weibull
model, there are three genes that substantially describe patients’ survival times,
namely GC-B (β1), lymphoma node (β2) and MHC (β5). These three genes have a
negative effect on the expected survival time. For the mixture model, GC-B (β1),
lymphoma node (β2) and proliferation (β3) accounted for patients’ survival times in
the first component. In the second component, GC-B (β1), lymphoma node (β2) and
MHC signature (β5) substantially explained patients’ survival times. All these genes
have negative effects on the expected survival time for their respective component.
For the cure model, four of these genes substantially describe patients’ survival
times, namely GC-B (β1), lymphoma node (β2), BMP6 (β4) and MHC signature
(β5). Three of these, namely GC-B (β1), lymphoma node (β2) and MHC signature
(β5), have a negative effect on the expected survival time. Under the cure model,
approximately 33.8% of the patients are cured of DLBCL (Figure 6.2).
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Figure 6.1: Kaplan-Meier estimates of overall survival according to the gene-
expression subgroups.
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Table 6.1: The estimated posterior mean of the parameters, the 95% credible
intervals (CI), the BIC values and the BMA weights for each of the fitted models
for the full DLBCL dataset.
Model Parameter Mean 95% CI BIC Weight
Weibull α 0.7305 (0.626,0.840) 687.0953 0.0009
β0 -1.578 (-1.84, -1.33)
β1 -0.3446 (-0.516, -0.172)
β2 -0.2844 (-0.454, -0.116)
β3 0.2097 (-0.049, 0.468)
β4 0.3292 (0.115, 0.537)
β5 -0.3019 (-0.488, -0.112)
Mixture α1 4.029 (2.411, 6.631) 734.0054 ≈ 0
α2 0.7707 (0.662, 0.885)
β01 6.857 (5.479, 8.205)
β02 -1.724 (-2.007, -1.457)
β11 -11.62 (-12.88, -10.35)
β12 -0.3956 (-0.575, -0.216)
β21 -2.087 (-3.54, -0.689)
β22 -0.3172 (-0.495, -0.143)
β31 -2.241 (-3.425, -1.059)
β32 0.1972 (-0.064, 0.461)
β41 -0.2849 (-1.434, 0.854)
β42 0.3594 (0.141, 0.574)
β51 -0.7928 (-2.107, 0.477)
β52 -0.3102 (-0.500, -0.115)
pi1 0.01992 (0.002, 0.053)
pi2 0.9801 (0.946, 0.997)
Cure α 0.9884 (0.828, 1.145) 673.1359 0.9991
β0 0.1611 (-0.124, 0.560)
β1 -0.3151 (-0.484, -0.144)
β2 -0.2821 (-0.451, -0.115)
β3 0.189 (-0.070, 0.442)
β4 0.3303 (0.118, 0.539)
β5 -0.3039 (-0.490, -0.112)
This is clearly exhibited in Table 6.1; when the weighting is based on the BIC
comparable across models, the cure model has the largest weight. To evaluate the
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model fit, a comparison of the density prediction for the models to the observed data
was carried out.
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Figure 6.2: Box-plots of the cure rates (posterior distribution of pi) for the full
DLBCL dataset, and to each of the three phenotypes (ABC, GCB and Type III).
Table 6.2 shows the 95% CI, BIC values and the BMA weights for each of the
models based on phenotype for the DLBCL dataset. In general, for all phenotypes,
the mixture model is not favourable as its weight value is approximately equal to
zero and it has the largest BIC value. On the other hand, the BIC values of the other
two models are close to each other, suggesting a combination of these two model in
order to account for the uncertainty in the prediction of survival.
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Table 6.2: The estimated posterior means of parameters, the 95% CI, BIC values
and the BMA weights for each of the models based on phenotype for the DLBCL
dataset.
Phenotype Model Variable Parameter Mean 95% CI BIC Weight
GCB Weibull α 0.692 (0.5365, 0.8595) 341.212 0.497
Intercept β0 -1.649 (-2.185, -1.17)
GCB β1 -0.179 (-0.5859, 0.239)
Lymphoma β2 -0.118 (-0.3958, 0.1607)
Proliferation β3 0.459 (-0.0306, 0.934)
BMP6 β4 0.414 (0.01773, 0.809)
MHC β5 -0.325 (-0.6389, -0.01228)
Mixture α1 4.252 (2.591, 7.175) 377.759 ≈ 0
α2 0.816 (0.6209, 1.032)
Intercept β01 6.491 (5.246, 7.781 )
β02 -2.152 (-2.798, -1.567)
GCB β11 -11.81 (-13.05, -10.53)
β12 -0.030 (-0.5104, 0.4592)
Lymphoma β21 -1.839 (-3.082, -0.6744)
β22 -0.134 (-0.48, 0.2254)
Proliferation β31 -2.165 (-3.313, -0.9932)
β32 0.588 (-0.07796, 1.407)
BMP6 β41 -0.242 (-1.357, 0.8482)
β42 0.654 (0.17, 1.161)
MHC β51 -0.629 (-1.993, 0.5117)
β52 -0.382 (-0.7687, -0.002227)
φ1 0.090 (0.02007, 0.1863)
φ2 0.91 (0.8137, 0.9799)
Cure α 0.845 (0.6075, 1.1) 341.188 0.503
Intercept β0 0.604 (-0.3556, 3.394)
GCB β1 -0.173 (-0.5754, 0.2402)
Lymphoma β2 -0.116 (-0.3891, 0.1579)
Proliferation β3 0.433 (-0.0522, 0.9041)
BMP6 β4 0.396 (-0.0007, 0.788)
MHC β5 -0.330 (-0.6422, -0.0209)
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Phenotype Model Variable Parameter Mean 95% CI BIC Weight
ABC Weibull α 0.894 (0.695, 1.115) 215.564 0.013
Intercept β0 -1.86 (-2.562, -1.217)
GCB β1 -0.509 (-0.9948, -0.03871)
Lymphoma β2 -0.626 (-0.9568, -0.3099)
Proliferation β3 -0.487 (-1.118, 0.1422)
BMP6 β4 0.645 (0.2725, 1.021)
MHC β5 -0.479 (-0.7955, -0.1598)
Mixture α1 2.427 (1.083, 4.152) 256.552 ≈ 0
α2 0.960 (0.7525, 1.189)
Intercept β01 6.636 (5.301, 7.959)
β02 -2.572 (-3.346, -1.865)
GCB β11 -12.11 (-13.36, -10.86)
β12 -0.925 (-1.438, -0.4356)
Lymphoma β21 -3.155 (-4.578, -1.75)
β22 -0.768 (-1.114, -0.4341)
Proliferation β31 -2.377 (-3.561, -1.188)
β32 -0.480 (-1.099, 0.1353)
BMP6 β41 0.079 (-1.064, 1.232)
β42 0.690 (0.3249, 1.061)
MHC β51 -0.644 (-1.919, 0.6499)
β52 -0.515 (-0.8176, -0.2047)
φ1 0.037 (0.0046, 0.09883)
φ2 0.963 (0.9012, 0.9953)
Cure α 1.189 (0.8906, 1.483) 206.961 0.987
Intercept β0 0.019 (-0.6417, 0.7362)
GCB β1 -0.432 (-0.8874, 0.01376)
Lymphoma β2 -0.587 (-0.905, -0.2867)
Proliferation β3 -0.484 (-1.076, 0.1012)
BMP6 β4 0.607 (0.2557, 0.9631)
MHC β5 -0.446 (-0.7481, -0.1346)
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Phenotype Model Variable Parameter Mean 95% CI BIC Weight
Type III Weibull α 0.834 (0.5958, 1.101) 162.27 0.538
Intercept β0 -1.75 (-2.736, -0.9093)
GCB β1 -0.404 (-1.028, -0.19)
Lymphoma β2 -0.274 (-0.7404, 0.1644)
Proliferation β3 0.506 (-0.0897, 1.084)
BMP6 β4 0.017 (-0.5301, 0.5206)
MHC β5 -0.199 (-0.6839, 0.3098)
Mixture α1 11.82 (8.609, 15.14) 196.271 ≈ 0
α2 0.596 (0.43, 0.7757)
Intercept β01 6.002 (3.682, 8.336)
β02 -5.005 (-7.19, -2.812)
GCB β11 -9.32 (-12.02, -6.611)
β12 0.564 (0.1829, 1.004)
Lymphoma β21 -2.913 (-5.716, -0.02716)
β22 -0.558 (-1.015, -0.1525)
Proliferation β31 -2.021 (-4.547, 0.455)
β32 0.893 (0.3455, 1.515)
BMP6 β41 0.320 (-2.466, 3.373)
β42 0.140 (-0.2735, 0.5384)
MHC β51 -0.336 (-2.733, 2.323)
β52 -0.293 (-0.7741, 0.1504)
φ1 0.072 (0.0108, 0.1805)
φ2 0.928 (0.8195, 0.9891)
Cure α 0.969 (0.6534, 1.339) 162.578 0.462
Intercept β0 0.989 (-0.5077, 4.153)
GCB β1 -0.349 (-0.973, -0.25)
Lymphoma β2 -0.269 (-0.7375, 0.1687)
Proliferation β3 0.502 (-0.0955, 1.084)
BMP6 β4 0.046 (-0.4801, -0.1801)
MHC β5 -0.183 (-0.6625, 0.3207)
From Tables 6.1 and 6.2, we can see that the Weibull model is better than a two-
component Weibull mixture model, suggesting the two-component mixture Weibull
is optimal as competing model.
As can be seen in Figure 6.3, in the full DLBCL dataset, the predicted curve for
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the cure model quite close to the observed data, suggesting a good fit of the data.
Specifically, in this model, 94.354% of observed survival times in the dataset fall in
the corresponding 95% prediction intervals. As expected, this is quite similar to the
result obtained from model averaging (91.935%) (Table 6.3).
Furthermore, in the GCB phenotype, the genes corresponding to the BMP6 (β4)
and MHC signature (β5) in the Weibull model and MHC signature in the cure model
substantially affect patients’ survival time. In the ABC phenotype, in the Weibull
model, with the exception of proliferation (β3), all genes were involved substan-
tially in the description of patients’ survival and lymphoma node (β2), BMP6 (β4)
and MHC signature (β5) are potentially important prognostic factors for predicting
survival in the cure model. For the type III phenotype, the GC-B (β1) gene in both
models and only the BMP6 (β4) gene in the cure model are substantial in explaining
the survival times of the patients.
Under the cure model, in the GCB phenotype, approximately 33.2% of the
patients are estimated to be cured of DLBCL. In the ABC and type III phenotypes,
the respective cure rates are approximately 26.57% and 18.7% (Figure 6.2).
Table 6.3: The percentage of observed values that lay in the corresponding 95%
credible interval for the individual models and BMA model based on the full
DLBCL dataset and each of the three phenotypes.
Model All DLBCL GCB ABC Type III
Weibull 87.516 90 89.130 89.286
Mixture 85.903 88 86.956 82.142
Cure 94.354 92 91.304 85.714
BMA 91.935 94 93.478 92.857
The results of the posterior densities prediction for the individual models and
the model averaged prediction based on these three phenotypes are presented in
Figure 6.3. In comparison to other models, the mixture model fitted the data poorly
for each phenotype. In detail, using model averaging, for the GCB phenotype, 94%
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of the observed survival times in the dataset lie in the respective 95% prediction
intervals. For the other two phenotypes, namely the ABC and the type III, 93.478%
and 92.857% of the observed survival times in the dataset are in the corresponding
95% prediction intervals, respectively (Table 6.3).
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Figure 6.3: The posterior densities of the three models and the model averaged
density for the full DLBCL dataset and each of the three phenotypes. For
comparison, the observed data is also represented as a histogram.
6.6 Discussion
This study has adopted a Bayesian model averaging approach to account for model
uncertainty in the prediction of survival. The case study that we considered involved
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lymphoma cancer survival, with covariates given by phenotypes and gene expres-
sions. Here, we proposed three competing models and used BMA to combine these
models to account for model uncertainty.
Overall, the results of this study indicate that if using the full dataset without
further grouping, selecting a single model that best fits the data was adequate.
The reason is that there is clear support for one model (i.e. only one model has
a relatively larger BIC value and dominates based on this criterion). However,
the results were different when the model selection process took into account the
phenotype subgroups of the patients. A single model appeared to be inadequate.
This was due to the fact that the values of BIC for the Weibull and the cure had
nearly equal weight, indicating the absence of a dominant model based on this
criterion and the presence of uncertainty issues in the model selection. As suggested
and shown in this study, BMA was used to address this problem. The applicability
of BMA was also associated with the smaller number of samples in each phenotype
subgroup (Annest et al., 2009, Volinsky et al., 1997, Yeung et al., 2005).
This study also revealed that in each phenotype, the expression and number of
predictor genes substantially describing the survival times of the patients varied
across models. Overall, in both of the favourable models, none of the genes existed
consistently as substantial predictors for the patients’ survival. For example, in the
Weibull model, the MHC and BMP genes in the GCB and ABC phenotypes and
the GCB genes in the ABC and Type III phenotypes were important predictors of
survival. In contrast, in the cure model, BMP was substantially associated with
predicted survival in the ABC and Type III phenotypes. For both models, only three
genes i.e. lymphoma node, BMP6 and MHC signature in the ABC phenotype were
highly associated with the survival times of the patients.
This study has indicated that the application of BMA to combine competing
132
CHAPTER 6. MODELLING SURVIVAL DATA TO ACCOUNT FOR MODEL
UNCERTAINTY
models overcomes the problem of uncertainty in the model selection process. Com-
parison of different survival models has allowed the identification and analysis of
the more detailed relationships between gene expressions in given phenotypes and
the survival times of the patients. The BMA approach enables us to provide more
precise predictions of patient survival. However, this study only involved three
candidate models. More models can be obviously included in the analysis. This
study has also focused on the marginal likelihood p(D | Qs) estimation methods
based on the Laplace approximation. However, other approaches are also possible.
Indeed marginal likelihood estimation is possible using nested sampling (Skilling,
2006), where the marginal likelihood is viewed as the expectation, with respect
to the prior, of the likelihood. The other approach is Chib’s method (Chib and
Greenberg, 1995), that presented a generic method which can be applied to output
from the Gibbs sampler. Applying BMA to other datasets, other applications where
robust prediction is desired.
Chapter 7
Conclusions and Future Work
7.1 General discussion
In this thesis, we developed and applied Bayesian modelling approaches for predic-
tion of patient survival using gene expression data and focused on two distinct areas,
covering both statistical methodology for Bayesian survival models and application
to gene expression data. Overall the results of this study have shown that Bayesian
models proposed including the Weibull model, the Weibull mixture model and the
Weibull cure model are robust to predict the patients’ survival using gene expres-
sion. The application of Bayesian model averaging (BMA) can produce better
descriptions of genetic contributors to survival and of subgroups of patients with
different survival characteristics. Censoring, which is an important issue in survival
analysis was also examined and proven to be influential for the performance of the
Weibull mixture models in terms of the bias and precision of parameter estimates. In
addition to this, censoring also had a differing effect depending on the “closeness”
of the components of the mixture. The application of BMA to combine the three
competing models had produced more robust results in relation to the problem of
the uncertainty in the model selection process. BMA has allowed the identification
and analysis of the more detailed relationships between gene expression in given
phenotypes and the survival times of the patients.
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A series of research studies have been conducted and followed through Chapters
4−6 to meet the outlined objectives. The specific finding and contributions from all
studies of this thesis in relation to lymphoma disease are summarised and outlined
under the objectives stated in Chapter 1.
Objective 1
We described and implemented the Bayesian Weibull model with MCMC compu-
tational methods to predict patient survival. The case study that we considered
involved lymphoma cancer survival, with covariates given by phenotype and gene
expressions. The construction of Bayesian survival models using gene expression
levels as covariates was discussed and published procedures were modified and
used accordingly. The issue of model choice through covariate selection was also
considered. Based on two goodness of fit criteria, we showed that selected genes
were substantially associated with survival in this study. Computation of DIC
and BIC estimates for all possible combinations of the covariates facilitated full
consideration of competing models. For example, models that are not best in the
sense of goodness of fit (based on these two criteria) may be interpretable with
respect to their biological and medical implications. A sensitivity analysis was also
conducted to assess the influence of the prior for each parameter. The sensitiv-
ity analysis conducted revealed that the model was reasonably robust to moderate
changes in the prior distribution. Apart from accuracy and precision criteria used
for the comparison study, the Bayesian approach coupled with MCMC enable us
to estimate the parameters of Weibull survival models and probabilistic inferences
about the prediction of survival times.
Based on the Bayesian Weibull model developed, this research revealed that
under BIC, four genes substantially described the survival of lymphoma patients,
including germinal centre B-cell signature, BMP6 signature, MHC class II sig-
nature, and proliferation signature. Meanwhile, using the DIC, apart from these
7.1. GENERAL DISCUSSION 135
genes, the phenotype also substantially explained the patients’ survival. These
facts suggest that patients with this molecular features will benefit most from the
current chemotherapy treatment. Furthermore, comparing the predicted survival
function for these four genes based on patients with different survival times, it was
shown the subject was located in the germinal center (GC) B-like DLBCL subgroup,
which had better likelihood of survival after chemotherapy than the activated B-like
DLBCL and Type III. If this subject resides in the GC B-like subgroup, and then
this subject has a reasonable chance of longer term survival. These findings are in
line with the study of Rosenwald et al. (2002) who concluded that the GC B-like
DLBCL had a significantly greater likelihood of survival after chemotherapy than
did the activated B-like DLBCL and Type III (Rosenwald et al., 2002).
Objective 2
In survival analysis, one of fundamental issues in the use of Weibull mixture models
is the effect of censored data. In relation to this, we examined the impact of
censoring on fitting two-component Weibull mixture models either with or without
covariates through the estimation of a two component Weibull mixture model in a
simulation study and through an application to a microarray dataset. The simula-
tion study was carried out with different parameter configurations of the mixture
model, that is, two well-separated components (M1) and two strongly overlapping
components (M2) for data generation, and five different levels of censoring. The
microarray dataset were collected from patients with Diffuse Large B-Cell Lym-
phoma (DLBCL). The results of the simulations show that censoring has an effect
on the performance of the Weibull mixture models in that, as the proportion of
censoring increases, poorer parameter estimates were obtained in terms of both bias
and precision. Our study also supports the work of Lagakos (1979) who indicated
that when the amount of censoring is small, very little bias is likely to result.
Censoring had a different effect on the mixture, depending on the “closeness” of
the components. These findings are in line with the study of Lagakos (1979) who
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concluded that the quality of estimates of parameters of a mixture model decreases
in the presence of increasingly larger levels of censoring. For the simulation study,
Type II censoring (Kalbfleisch and Prentice, 2002, Lawless, 2002) was used to
generate the data.
We also addressed label switching to deal with non-identifiability of the mixture
components. Label switching is a known problem in mixture model analysis. The
problem arises from the invariance of the likelihood with respect to the permutations
of the component labels in the mixture model. As a result, the marginal distributions
of the parameters are identical for all components and the posterior expectations for
the parameters are also identical. In this thesis, the approximate maximum a poste-
riori (MAP) (i.e. the realization of parameters corresponding to the MCMC iterate
that maximised the unnormalised posterior) was chosen as the pivot. This approach
worked well in correcting label switching in the MCMC output. Apart from bias and
precision criteria used for investigating the impact of censoring in the finite mixture
of Weibull distribution, the Bayesian approach coupled with MCMC enable us to
estimate the parameters of Weibull mixture survival models for dealing with such
censored data situations, maintain identifiability and deal with the problem of label
switching.
As mention earlier in Chapter 5, the DLBCL dataset used in this study comprises
43.4% censored patients. However, this is acceptable as we have shown censoring
up to 80% that can result in a break-down of the mixture estimation. In relation to
this, and given the two components of the Weibull mixture model, the role of each
genes in explaining the survival of patients is varied. The only lymphoma signature
in the first component and GC-B signature, lymphoma signature, proliferation sig-
nature, BMP6 signature and MHC signature in the second, substantially described
patients’ survival times. With respect to the effect of genes, the only lymphoma
signature in the first component, and GC-B signature and MHC signature had a
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negative effect on the expected survival time, meaning that these genes lead to a
better survival prognosis (Farcomeni and Nardi, 2010).
Objective 3
A variety of methodologies exist to compare several competing models for a given
dataset and to select the one that best fits the data. Bayesian model averaging
(BMA) is one way of combining models in order to account for the uncertainty
present in the model selection process. We have conducted analysis to describe
and evaluate the model averaging approach to account for model uncertainty in the
prediction of survival. The case study that we used involved lymphoma cancer
survival, with covariates given by phenotypes and gene expressions. We proposed
three competing models (Weibull model, Weibull mixture model and cure model)
and used BMA to combine the predictions arising from these models. The results of
this study indicated that when using the full datasets with sufficiently large sample
size without further grouping, selecting a single model that best fits the data is
adequate. In our case, the cure model was the preferred model based on all of the
patients in the DLBCL dataset as it had a dominant value of BIC as an information
criterion reflecting the goodness of fit of the model. However, the results are
different when the model selection process is based on the phenotype subgroups
of the patients. A single model seems to be inadequate in that substantially model
uncertainty was displayed.This may be a result of the reduced sample size (Annest
et al., 2009, Volinsky et al., 1997, Yeung et al., 2005). As suggested and shown
in this study, BMA was used to address this problem. This study also revealed
substantial variation between phenotype groups with respect to the expression and
number of predictor genes in each favourable model substantially describing the
survival times of the patients. For example, in the Weibull model, the MHC and
BMP genes in the GCB and ABC phenotypes and the GCB genes in the ABC and
Type III phenotypes were important predictors of survival. In contrast, in the cure
model, BMP was substantially associated with predicted survival in the ABC and
138 CHAPTER 7. CONCLUSIONS
Type III phenotypes. For both models, only three genes i.e. lymphoma node, BMP6
and MHC signature in the ABC phenotype were highly associated with the survival
times of the patients.
The application of BMA to combine competing models overcomes the problem
of uncertainty in the model selection process. Comparison of different survival
models has allowed the identification and analysis of the more detailed relationships
between gene expressions in given phenotypes and the survival times of the patients.
7.2 Future work
As discussed in each component of this thesis, extensions and development of
the proposed and adapted methods can be followed. Indeed, the development of
Bayesian modelling approaches for prediction of patient survival presents many
possibilities for future work. As discussed in Chapter 4, it may be worthwhile to
pursue the Reversible Jump Markov Chain Monte Carlo (RJMCMC), proposed by
Green (1995) and described in a general context by Lunn et al. (2009) as an alter-
native approach to post-analysis model comparison and BMA. It may be possible
to apply this model comparison by transforming the Weibull model to the extreme
value model.
The other research area that is not featured in this thesis but presents opportuni-
ties for future work is the use of random censoring (Liu, 2012, Miller, 1998) in the
simulation study to generate the data in Chapter 5. This censoring mechanism is
also commonly encountered in practice and could have been explored to investigate
the impact of different censoring mechanisms on mixture model estimation.
The research in Chapter 6 indicated that BMA approach enables us to provide
more precise predictions of patient survival. However, this study only involved three
candidate models. More models can be obviously included in the analysis. This
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study has also focused on the marginal likelihood p(D | Qs) estimation methods
based on the Laplace approximation. However, other approaches are also possible.
Indeed marginal likelihood estimation is possible using nested sampling (Skilling,
2006), where the marginal likelihood is viewed as the expectation, with respect
to the prior, of the likelihood. The other approach is Chib’s method (Chib and
Greenberg, 1995), that presented a generic method which can be applied to output
from the Gibbs sampler. Applying BMA to other datasets, other applications where
robust prediction is desired.
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